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Abstract 
 
 The primary objective of my thesis work is to establish a set of design criteria for 
nanoparticles whose purpose is to safely and efficiently access the brain after systemic 
injection.  Nanoparticles that can access the brain may be able to deliver therapeutic 
molecules to the brain that otherwise would be excluded by the blood-brain barrier.  
E. coli glycoprotein 96 (Ecgp96) is explored as a candidate receptor on the blood-
brain barrier that could potentially facilitate nanoparticle-receptor mediated transcytosis 
into the brain.  Results from studies utilizing PET/CT, SPECT/CT, MRI, Xenogen 
fluorescence imaging, and confocal microscopy conclude that Ecgp96 is observed in the 
blood-brain barrier endothelial cells, but is not accessible from the blood of adult or 
neonatal mice under normal, non-pathological conditions.   
Transferrin receptor is a well-characterized receptor on the blood-brain barrier 
that is accessible from the blood and known to transcytose transferrin.  I focused on this 
receptor and on synthesizing and characterizing a well-defined set of transferrin 
containing gold nanoparticles of various sizes and transferrin compositions that would be 
investigated during in-vivo studies.  Nanoparticle sizes were measured by DLS and 
nanoparticle tracking analysis.  Zeta potentials were also measured.  Nanoparticle 
transferrin content was directly measured by labeling transferrin with 64Cu and measuring 
the nanoparticle associated gamma activity.  The nanoparticle binding avidities to mouse 
transferrin receptors were ranked by a silver enhancement fluorescence-based method 
using the mouse Neruo2A cell line.  
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Each nanoparticle formulation was systemically injected into mice, and 
localization in the mouse brain was observed by silver enhancement light microscopy, 
and TEM.  The quantitation of the gold was determined by ICP-MS.  Nanoparticles with 
large amounts of transferrin remain strongly attached to brain endothelial cells, while 
nanoparticles with less transferrin are capable of both interacting with transferrin receptor 
on the luminal side of the blood-brain barrier and detaching from transferrin receptor on 
the brain side of the blood-brain barrier.  These results highlight the fact that the 
nanoparticle avidity must be tuned to maximize the number of nanoparticles exiting the 
endothelial cells and entering the brain tissue.  Lanthanum nitrate perfusion-fixation 
studies demonstrate that the nanoparticle formulations investigated do not degrade the 
blood-brain barrier integrity and enter the brain by transferrin receptor-mediated 
transcytosis.  The results from these studies provide initial design criteria for creating 
nanoparticle therapeutics for delivery to the brain from systemic administrations. 
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Chapter 1:  Introduction 
 
 Cardiovascular diseases and cancers have been a major focus of biomedical 
research over the past several decades as these diseases have been the predominant cause 
of morbidity and mortality in the United States [1].  The next major focus of biomedical 
research will likely be on diseases of the brain, such as Alzheimer’s disease.  The baby 
boomer generation is quickly reaching advanced age (65 and over) and therefore a 
concurrent increase in the incidence of diseases of the elderly such as Alzheimer’s 
Disease is expected [2].  In 2012, 5.4 million Americans above the age of 65 had 
Alzheimer’s disease, and by 2050, as many as 16 million will have the disease [3].  
 Treating Alzheimer’s disease and other related diseases of the brain has recently 
become a national priority.  In addition to the estimated 200 billion dollars spent by 
families in 2012, 200 billion dollars was spent by the federal government on Alzheimer’s 
disease care (roughly five percent of the federal budget) [3].  To establish a national 
initiative and help direct researchers in finding solutions to Alzheimer’s disease, in 
January 2011 the National Alzheimer’s Project Act (NAPA) was signed into law.  
Included in the goals of NAPA is the development of effective prevention and treatment 
approaches for Alzheimer’s disease and related dementias by 2025 [4].  
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Figure 1.1: Statistics on Alzheimer’s Disease – figure from [3].  (Left Panel) Rates of 
mortality due to cancers, cardiovascular diseases, and infectious diseases have decreased 
over the last decade.  Deaths due to brain diseases such as Alzheimer’s Disease are on the 
rise.  (Right Panel) The costs associated with treating and caring for patients with brain 
diseases is reaching five percent of the federal budget, and costs are continuing to rise as 
the population continues to age. 
 
In order to meet the goals of NAPA, new strategies for treating brain diseases 
must be approached.  Traditionally, brain diseases have been treated by oral 
administration of small molecule therapeutics that distribute throughout the body and 
indiscriminately flood the brain.  During a 2013 lecture at Caltech’s TEDx The Brain, 
Caltech professor David Anderson eloquently composed an analogy describing this 
current strategy for treating brain diseases and the problems that arise from it: 
“…A lot of people won’t take them [medications]…because of 
their unpleasant side effects.  These drugs have so many side effects, 
because using them to treat a complex psychiatric disorder is a bit like 
trying to change your engine oil by opening a can and pouring it all over 
the engine block.  Some of it will drip into the right place, but a lot of it 
will do more harm than good.” 
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This highlights the major issues that must be addressed when designing the next 
generation of therapeutics for brain diseases.  New therapeutics need to be developed 
with reduced side effects, and these therapeutics need to be delivered specifically to the 
sites of pathology in the brain.  The next generation of brain therapeutics is likely to be 
made of larger molecules, such as siRNA [5, 6], that contain more chemical information 
and can more specifically treat a disease with reduced side effects.  However, these large 
molecule therapeutics may be ineffective at treating brain diseases because they cannot 
access the brain due to the blood-brain barrier (see below).  
There are currently four cholinesterase inhibitor-based medications approved for the 
treatment of Alzheimer’s disease (donepezil, galantamine, rivastigmine, and tacrine – 
memantine is an NMDA receptor antagonist also approved for the treatment of the 
disease). These medications are used only to treat the memory loss symptoms of 
Alzheimer’s disease and do not treat the underlying cause of the disease.  Also, these 
therapeutics are prescribed when the patients already exhibit the most crippling symptom 
of the disease – memory loss.  Therefore there is great need for developing therapeutics 
that treat the underlying pathology of Alzheimer’s disease and significantly delay the 
onset of the disease and its memory loss symptoms.  Decreasing the overall prevalence of 
Alzheimer’s disease by delaying its onset will be paramount to geriatric quality of life, 
and significant in offsetting the financial burden felt by individual families and the 
economic burden felt by the nation [7]. 
To accomplish this, the disease must first be diagnosed and treated well before the 
onset of symptoms. Improved imaging studies including positron emission tomography 
of amyloid beta aggregate binding-Pittsburgh compound B (PIB) are quickly advancing 
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and could potentially make pre-mortem diagnoses possible well before the onset of 
memory loss [8-10].  New therapeutics designed to target the underlying pathophysiology 
of Alzheimer’s Disease (amyloid beta aggregation and resulting neuronal cell death) are 
also being tested in clinical trials [11].  Amongst the recently completed phase III clinical 
trials, two therapeutics were tested that targeted amyloid beta aggregation in the brain 
(gamma secretase inhibitor Ly450139, and ‘selective amyloid beta 42 lowering agent’ 
MPC-7869 (or tarenflurbil)).  Both therapeutics failed to continue beyond phase III trials.   
Like the current FDA approved drugs for Alzheimer’s disease, Ly450139 and MPC-
7869 are both small molecules below 400 Da [12, 13]).  Medications currently on the 
market for brain diseases and therapeutics that target a pathology within the brain are 
limited to small (molecular weight less than 400 Da) lipophilic molecules because these 
molecules can cross the blood-brain barrier (see below) [14].  One of the largest 
difficulties in therapeutic development for diseases of the brain is that any therapeutic 
currently developed to reach the brain must meet these criteria: they must be small 
molecules and have chemical compositions that allow passage across the blood-brain 
barrier.  Any therapeutic currently being tested to treat a brain disease is therefore highly 
limited in chemical composition by these requirements. 
The Blood-Brain Barrier 
The blood-brain barrier is composed of brain microvascular endothelial cells, the 
tight junctions between those cells, cell efflux pump systems, and supporting cells such 
as astrocytes and their foot processes [15].  The blood-brain barrier was initially observed 
by Paul Ehlrich in 1885 after systemically injecting vital dyes into animals and observing 
that these dyes distributed throughout the body, except for the brain [16].  The blood-
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brain barrier is important to tightly regulating the brain’s microenvironment and 
protecting the brain from harmful outside agents [15].   In certain conditions such as 
cases of juvenile bacterial meningitis, medical emergencies are indicated when the blood-
brain barrier is breached and bacteria are found on cerebral spinal fluid cultures [17].  It 
is therefore important that the blood-brain barrier functions well at excluding foreign 
agents from entering the brain in order to protect the brain.  Though isolating the brain 
from the external environment and protecting the brain from foreign agents is vitally 
important, it is also a major problem when developing new therapeutics for brain 
diseases, as potentially functional therapeutics will be excluded from the brain by the 
blood-brain barrier.  
An exceptional pharmaceutical success story in the treatment of Parkinson’s 
disease is that of L-DOPA, which is a prodrug and precursor to dopamine.  The 
pharmacologic mechanism of L-DOPA is a triumph in blood-brain barrier related 
chemistries and highlights the necessity for developing therapeutics whose chemical 
composition allows passage across the blood-brain barrier as well as contains 
functionality in targeting a molecular pathophysiologic mechanism.  L-DOPA is 
administered to Parkinson’s disease patients to increase the concentration of dopamine in 
the brain, especially at the point of pathology in the substantia nigra.  Dopamine itself 
does not cross the blood-brain barrier, however L-DOPA contains an extra carboxylic 
acid group on its terminal carbon that allows it to cross the blood-brain barrier through 
receptor mediated transcytosis [18].  Once in the brain, the carboxylic acid is cleaved 
from L-DOPA by DOPA decarboxylase to form dopamine [19].  In addition to L-DOPA, 
carbidopa can be concurrently administered to the patient.  Carbidopa is an analogue of 
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L-DOPA that does not cross the blood-brain barrier and can inhibit DOPA decarboxylase 
in the peripheral circulation [19].  This increases the concentration of available L-DOPA 
to cross the blood-brain barrier where it then can be converted to dopamine by brain 
associated DOPA decarboxylase. 
Designing therapeutics such as L-DOPA that contain chemical compositions that 
allow passage across the blood-brain barrier is problematic as this is highly difficult to 
accomplish and greatly reduces the number of potential therapeutics that otherwise would 
contain good therapeutic functionality.  Though a solution for delivering dopamine to the 
brain was found, the story of L-DOPA is more the exception than the rule.  Therefore 
new approaches must be considered to circumvent the blood-brain barrier that do not 
involve modifying the chemistries of the therapeutic molecules so they contain blood-
brain barrier permeability properties.  This means that a new approach must be developed 
that can deliver any therapeutic molecule into the brain, regardless of the molecular size 
or chemical composition. 
Numerous multidisciplinary-based strategies to transport therapeutic agents from 
the blood into the brain have been proposed [20].  Among the strategies currently being 
explored to deliver therapeutics into the brain include blood-brain barrier disruption 
(mannitol [21], ultrasound [22], adenosine [23]), antibody-drug conjugate systems [24],  
and various types of targeted and untargeted nanoparticle systems (liposomes [25], PBCA 
[26], and targeted exosomes [27]).  The strategy taken in this thesis work is of receptor-
mediated transcytosis of nanoparticle drug delivery vehicles.  Receptor mediated 
transcytosis naturally occurs at the blood brain barrier, and is responsible for delivering a 
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variety of proteins to the brain that are necessary for the brain to function properly, such 
as the iron-carrying protein, transferrin [28].   
Receptor mediated transcytosis at the blood-brain barrier takes advantage of 
receptors on the endothelial cells that bind to their ligand from the blood, aid in 
internalizing their ligand into vesicles that are transported to the brain side of the 
endothelial cell, and release the protein into the brain once the vesicle fuses with the cell 
membrane on the brain side of the endothelial cell (Figure 1.2).  These receptors that 
facilitate receptor-mediated transcytosis can be tricked into carrying nanoparticles across 
the blood-brain barrier by coating the nanoparticles with the protein that normally is 
transcytosed (Figure 1.3 and 1.4).  Several receptors have been reported to facilitate 
receptor mediated transcytosis at the blood-brain barrier, most notably the transferrin 
receptor [28, 29], insulin receptor [30, 31], and low density lipoprotein receptor-related 
protein [32].  In addition, phage libraries have been employed to find new ligands to 
unknown blood-brain barrier receptors that could potentially facilitate receptor-mediated 
transcytosis in-vivo[33, 34]. 
  Receptor mediated transcytosis of antibodies [35] and nanoparticles [26] across 
the blood brain barrier have been reported.  Of interest concerning the transferrin receptor 
(the receptor of focus in this thesis work), Friden et al. report of a low affinity (nearly 
identical to transferrin-transferrin receptor interaction strength) antibody that significantly 
accumulated in the brain parenchyma after receptor mediated transcytosis [35].  Also 
lactoferrin modified nanoparticles (lactoferrin binds to transferrin receptor) were shown 
by TEM to be transported into the brain parenchyma through receptor-mediated 
transcytosis [36].   
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Figure 1.2: Schematic of receptor-mediated transcytosis of a protein.  A protein in the 
blood attaches to its receptor on the surface of the blood-brain barrier and is endocytosed 
into vesicle of the endothelial cell.  The endocytic vesicle is transported across the 
endothelial cell, and once it arrives on the brain side of the blood-brain barrier, the 
vesicle fuses with the cell membrane and the protein is released into the brain 
parenchyma.  
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Figure 1.3: Nanoparticles can be created to contain protein that binds to receptors on the 
blood-brain barrier.  The protein is attached to the surface of the nanoparticles through a 
polyethylene glycol (PEG) polymer.  Additional PEG is added to the surface of the 
nanoparticles (PEGylation) in order to provide stability in high ionic solutions such as 
blood. 
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Figure 1.4:  Receptor mediated transcytosis of nanoparticles.  Nanoparticles containing 
protein that attaches to receptors on the blood side of the blood-brain barrier can be 
endocytosed into vesicles and transported across the endothelial cells (denoted capillary 
in this figure), and once on the brain side of the blood-brain barrier, can be released into 
the brain parenchyma. 
 
Nanoparticles for Delivery of Therapeutics across the Blood-Brain Barrier 
  Nanoparticles have many advantages for drug delivery on which comprehensive 
reviews have been written [37].  Most relevant for delivery to brain, they mask (but do 
not alter) the chemical composition of the therapeutic being delivered, which reduces 
toxicity and eliminates the need for designing small (<400 Da) molecules with highly 
specific chemistries for blood-brain barrier passage [14].  Nanoparticles also shield the 
small molecule therapeutics from p-glycoprotein efflux pump systems in the blood-brain 
barrier, which eliminates endothelial cell rejection of drug back into the blood [38-40].  
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Most importantly for drug delivery to the brain by receptor-mediated transcytosis, the 
nanoparticle provides a platform on which ligands can be attached that specifically target 
transcytosing receptors on the blood-brain barrier.  These ligands have been shown to 
trick receptors into carrying a nanoparticle with payload of interest through the 
endothelial cell where the therapeutic can be released by the nanoparticle into the brain 
parenchyma [41]. 
  Targeted nanoparticles are finding application for the delivery of a wide variety of 
therapeutic agents, and several have already reached clinical testing in humans[42, 43]. 
For example, a transferrin-containing nanoparticle was used to deliver siRNA to cancer 
patients in a Phase I clinical trial, and shown to deliver functional siRNA to melanoma 
tumors in a dose dependent manner [44]. Those results demonstrate that transferrin-
containing nanoparticles can be safely administered to humans.  There are a number of 
nanoparticle based therapeutics that have already reached clinic trials as wells as a few 
that are now commercially available (e.g. liposome based Doxil) [42]. 
  Multiple nanoparticle studies of receptor mediated transcytosis across the blood 
brain barrier have shown that nanoparticles can accumulate in the brain when they 
contain a ligand for blood-brain barrier receptor targeting [45-47].  Targeted 
nanoparticles have also been shown to facilitate internalization of nanoparticles into 
tumor cells, but the addition of targeting ligand does not significantly change the overall 
biodistribution of the nanoparticles [48].  Targeted ligand therefore affects the ability of 
the nanoparticle to be internalized by tumor cells in-vivo and also affects the ability of 
nanoparticles to be internalized by blood-brain barrier endothelial cells in-vivo.   
  Proof of nanoparticle accumulation in the brain parenchyma is normally 
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accomplished by TEM imaging of the nanoparticles in the brain parenchyma as well as 
the blood-brain barrier endothelial cells [26, 36, 46].  In-vivo confocal microscopy has 
also shown evidence that certain types nanoparticles can enter the brain parenchyma [26, 
49].  Many nanoparticle studies of the blood-brain barrier quantitate the accumulation of 
nanoparticles in the brain by perfusing the animal with a saline solution post-mortem to 
remove blood-associated nanoparticles and measuring the bulk brain nanoparticle content 
by various methods[45, 46].   
  This perfusion method has been a mainstay in providing evidence that the 
addition of targeting ligand to the nanoparticle increases the accumulation of the 
nanoparticle in the brain.  However it has yet to be shown that these nanoparticles 
accumulate in the brain parenchyma as opposed to remaining stuck in the vasculature, 
which would be consistent with the analysis provided by Paris-Robidas [50] that focuses 
on antibodies attaching to the blood-brain barrier transferrin receptors.  The accumulation 
of nanoparticles in the vasculature would also be more consistent with the long-standing 
dogma that the blood-brain barrier is effective at keeping most foreign agents from 
entering the brain.   
  In this thesis work, silver enhanced light microscopy (previously unused in 
nanoparticle-based brain studies) was developed in order to quantitate the number of 
nanoparticles that remain associated with the blood-brain barrier endothelial cells as 
opposed to the number of nanoparticles which release from the endothelial cells and enter 
the brain parenchyma.  This work gives first insights into the design criteria necessary for 
maximizing the number of nanoparticles that reach the brain parenchyma as opposed to 
maximizing the number of nanoparticles that accumulate in the bulk of the brain mainly 
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by remaining stuck to the blood-brain barrier endothelial cells. In addition, nanoparticle 
safety is a concern, as nanoparticles with certain characteristics (nanoparticles that are 
highly positively charged) degrade the blood-brain barrier [51]. Studies to prove that the 
blood-brain barrier remains intact have been performed by various methods, including 
lanthanum nitrate perfusion fixation [52]. These blood-brain barrier integrity studies are 
also employed in this thesis work. 
Thesis Objectives and Organization 
 
The main objective of this thesis work is to establish a set of design criteria for 
nanoparticles whose main purpose is to safely and efficiently access the brain after 
systemic injection.  Nanoparticles that can access the brain may be able to deliver 
therapeutic molecules to the brain that otherwise would be excluded from the brain by the 
blood-brain barrier.  Therefore, nanoparticles may become a key element for a new 
strategy in treating brain diseases by acting as therapeutic delivery vehicles that can cross 
the blood-brain barrier.   
This thesis is written in three main parts.  The first part explores a candidate 
receptor on the endothelial cells of the blood-brain barrier that could potentially facilitate 
nanoparticle-receptor mediated transcytosis through the blood brain barrier.  This 
candidate receptor is E. coli glycoprotein 96 (Ecgp96).  The potential importance of this 
candidate is that it was proposed to be accessible from the blood only at the blood-brain 
barrier and nowhere else in the body.  Therefore it had the potential to deliver 
nanoparticles only to the brain; otherwise the nanoparticles would be removed from the 
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several imaging studies using five different imaging modalities, it was concluded that 
Ecgp96 was located inside the blood brain barrier endothelial cells, but was not 
accessible from the blood in-vivo as originally proposed. 
The second part of this thesis work focuses on synthesizing and characterizing a 
well-defined set of nanoparticles that would be investigated during in-vivo blood-brain 
barrier receptor mediated transcytosis studies.  These nanoparticles are composed of gold 
and contain transferrin that is used to target the transferrin receptor at the blood-brain 
barrier.  Unlike Ecgp96, the transferrin receptor is expressed throughout the body and is 
also well accepted to exist on the blood-brain barrier and facilitate receptor mediated 
transcytosis of iron into the brain facilitated by the iron binding protein transferrin.  Gold 
nanoparticles of increasing sizes were coupled with increasing amounts of transferrin.  
The transferrin contents of each nanoparticle formulation were directly measured through 
64Cu quantitative studies, the sizes were measured through dynamic light scattering and 
nanoparticle tracking analysis, the zeta potentials were measured with a Brookhaven 
Instruments ZetaPals, and the binding avidities to transferrin receptor (or effective 
nanoparticle binding strength to mouse cell associated transferrin receptors) were 
measured using a silver enhancement fluorescence-based method.  Nanoparticle avidity 
was found to increase with increasing transferrin content, and a weak effect of increasing 
size on increased binding was observed. 
The third part of this work was focused on understanding how each nanoparticle 
synthesized interacted with the blood-brain barrier in-vivo.  Each nanoparticle 
formulation was systemically injected by lateral tail vein injection, and its behavior in the 
brain was observed by silver-enhancement light microscopy, and transmission electron 
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microscopy (TEM).  Bulk amounts of gold in the brain were measured by ICP-MS.  
Nanoparticles with high transferrin content accumulated more in the bulk of the brain (as 
measured by ICP-MS) as well as in the blood vessels/endothelial cells (as measured by 
silver enhancement light microscopy and TEM).  Most importantly, it was shown by 
silver-enhancement light microscopy that nanoparticle avidity must be tuned to maximize 
the number of nanoparticles exiting the endothelial cells and entering the brain tissue 
(called the ‘brain parenchyma’ or just ‘parenchyma’).   
Nanoparticles of both 45 nm and 80 nm diameter reached the brain parenchyma, 
and their accumulation there was observed to depend on transferrin content. 
Nanoparticles with large amounts of transferrin remain strongly attached to brain 
endothelial cells, while nanoparticles with less transferrin are capable of both interacting 
with transferrin receptor on the luminal side of the blood-brain barrier and detaching 
from transferrin receptor on the brain side of the blood-brain barrier. TEM imaging of 
brain sections from mice perfused with lanthanum nitrate provided evidence that 
nanoparticles did not degrade the blood-brain barrier integrity, and that transferrin-
containing nanoparticles reached the parenchyma via a receptor-mediated transcytosis 
pathway. 
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Chapter 2:  E. coli Glycoprotein 96 
Introduction  
 
Current targeted delivery of nanoparticles into the brain takes advantage of blood-
brain barrier receptors that are ubiquitously expressed such as the transferrin receptor, 
lipoprotein receptors (ApoE), and insulin receptors [1]. Our lab was approached by a 
group at Children’s Hospital Los Angeles headed by Dr. Nemani Prasadarao who 
suggested investigating a new protein that had not previously been studied for targeted 
delivery of nanoparticles to the brain. This protein was a neonatal E. coli meningitis 
associated protein, E. coli glycoprotein 96 (Ecgp96), which interacts with E. coli on the 
surface of brain endothelial cells. Dr. Prasadarao proposed the development of a 
nanoparticle that would target Ecgp96 for receptor-mediated transcytosis across the 
blood-brain barrier in-vivo. The novelty of targeting the Ecgp96 receptor was that it was 
thought to be surface expressed only on endothelial cells of the blood-brain barrier; 
therefore, targeted delivery through Ecgp96 should only send nanoparticles to the brain - 
otherwise the nanoparticles should be cleared by the body’s normal filtration process 
through kidney and liver. 
In 1997, Dr. Prasadarao and co-workers first proposed that Ecgp96 was located on 
endothelial cells only in the brain [2].  They since have proposed that Ecgp96 is the 
receptor that facilitates E. Coli meningitis in new-born infants. Prasadarao et al. 
demonstrated that E. coli outer membrane protein A (OmpA), which is characteristic to 
the strain of E. coli that causes meningitis in newborn infants, binds to a 95 kDa 
glycoprotein-type receptor (Ecgp) on human brain microvascular endothelial cells 
(HBMECs) [3]. In this work, Prasadarao et al. demonstrated that Ecgp clustered on 
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HBMEC at the site of OmpA+ E. coli invasion but no clustering occurred with OmpA- E. 
coli.  Ecgp was later positively identified as a glycoprotein 96 homologue by screening 
an HBMEC cDNA expression library with an anti-Ecgp96 antibody [4]. 
Ecgp96 (also known as grp94) is a member of the heat shock protein (hsp90) family, 
which is responsible for a number of important molecular processes including the 
insurance of correct protein folding [5]. Grp94 is the most abundant chaperone protein 
inside the endoplasmic reticulum [6], and is believed to be mainly located within the 
lumen of the endoplasmic reticulum [7]. Under conditions of stress, grp94 has been 
shown to be transported to the outer surface of the plasma membrane through the loss of 
its endoplasmic reticulum retention signal KDEL [8]. In a paramount review of hsp90 
and grp94, Csermely, et al., noted that easy mobility seems to be a phenomenon of 
endoplasmic reticulum lumen proteins, which makes grp94 versatile by its facile ability 
to redistribute to different cellular compartments [5]. Though the roles of Ecgp96 are 
many, it is yet to be proven that Ecgp96 is directly responsible for transporting E. coli 
across the blood-brain barrier via receptor-mediated transcytosis in-vivo. 
Ecgp96 was described to be only on endothelial cells of the blood-brain barrier 
through screening endothelial cells from four locations in the body: HBMEC, human 
umbilical vein, human aortic arterial, and human iliac vein endothelial cells [2]. 
Confirmation that Ecgp96 is exclusively on brain endothelium and is accessible from the 
blood in-vivo remains to be completed, and is the first focus of this thesis work.  Though 
direct evidence supporting the use of Ecgp96 for nanoparticle delivery across the blood-
brain barrier in-vivo is needed, there are studies that indirectly support the idea of 
targeting nanoparticles to Ecgp96 for delivery to the brain. These papers demonstrate the 
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OmpA/Ecgp96 interaction is essential for the invasion of E. coli across the blood-brain 
barrier not only in-vitro but also in-vivo [9, 10]. In these studies OmpA mutant E. coli 
that are less able to interact with Ecgp96 were found to be less invasive in HBMEC in-
vitro and were also found to be significantly less able to penetrate into the central nervous 
system in-vivo as measured by cerebral spinal fluid cultures. 
OmpA positive E. coli have been shown to degrade blood-brain barrier integrity 
in-vitro as measured by trans-endothelial electrical resistance (TEER) [11].  Thus safety 
concerns may preclude developing nanoparticle drug delivery vehicles targeted to 
Ecgp96 for use in humans.  Tight junction degradation was hypothesized to occur via 
OmpA mediated stimulation of iNOS (inducible nitric oxide synthase), generation of 
cGMP, and induction of αPKC (alpha protein kinase C). Results from the same paper 
show that OmpA+ E. coli are capable of increasing HBMEC surface expression of 
Ecgp96 by twofold, presumably through the same proposed mechanism. This suggests 
OmpA+ E. coli could be crossing the blood-brain barrier not by Ecgp96 receptor 
mediated transcytosis, but instead by passing through the paracellular pathway after 
OmpA mediated tight junction degradation. This would lead to acute inflammation that 
would be harmful to the patient [12] and is therefore not ideal for a well engineered 
nanoparticle drug delivery system that would be administered in patients with chronic 
neuropathological conditions. 
Organization and Summary of Results 
The first step in developing a nanoparticle targeted to Ecgp96 for delivery to the 
brain was to confirm that Ecgp96 is located on the surface of brain endothelial cells and 
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accessible from the blood in-vivo. After four experiments using four different imaging 
modalities, the evidence was clear that the Ecgp96 receptor was not accessible from the 
blood on the brain endothelium luminal surface. Ecgp96 was found to be present in brain 
endothelial cells by confocal microscopy, however it was not accessible via the blood and 
thus not available for therapeutic delivery across the blood-brain barrier. 
The first experiment probed for Ecgp96 expression on the blood-brain barrier 
through systemic injection of a 64Cu radiolabeled antibody against Ecgp96 into an adult 
mouse followed by imaging the brain using Positron Emission Tomography/Computed 
Tomography (PET/CT). PET is a highly sensitive method for locating radioactive signal 
in-vivo.  No positron signal from Ecgp96 antibody was seen in the brain by PET, though 
antibody was observed to circulate in the blood and accumulate in the liver.  Further 
experimentation with additional imaging modalities were chosen to confirm that Ecgp96 
was not located on the blood-brain barrier of the mouse and that antibodies to Ecgp96 did 
not accumulate in the brain. 
The next experiment was to systemically inject a fluorophore labeled antibody to 
Ecgp96 and monitor for accumulated signal in the brain using fluorescence Xenogen 
imaging. This modality does not provide three-dimensional images like PET, and unlike 
PET, fluorescence Xenogen imaging is limited in sensitivity by the tissue penetration 
depth the emitted light must travel through. After injection and imaging, the bulk signal 
from the Ecgp96 antibody-treated brain was no different from the non-injected control 
brain, indicating no observable accumulation of the antibody in the brain. 
It was concluded from the PET and Xenogen imaging biodistribution studies that 
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Ecgp96 was not accessible from the blood on the blood-brain barrier of adult mice.  Since 
E. coli meningitis is a disease of neonatal infants and Dr. Prasadarao’s research focused 
on neonatal mice, it was hypothesized that Ecgp96 would be expressed on neonatal 
mouse brain endothelium but not on adult mouse brain endothelium.  The UCLA 
veterinarian did not work with neonatal mice, so PET scan biodistribution studies could 
not be employed on neonatal mice there. SPECT/CT imaging could be carried out on 
neonatal mice at the Small Animal Imaging Research Center (SAIRC) at Children’s 
Hospital Los Angeles.  A biodistribution study of Ecgp96 in neonatal mice utilizing 
SPECT/CT after injection of an 111In radiolabeled antibody against Ecgp96 was therefore 
employed.  SPECT is very similar to PET in that three-dimensional images can be 
generated from in-vivo signal, however SPECT is less sensitive and has lower spatial 
resolution.  
In this experiment, a lead shield was placed around the body of the mouse to 
eliminate washout signal from non-brain regions (heart and liver) so that a high 
instrument detection gain could be used to pick up any small amount of gamma-radiation 
that may be present in the brain. The brain of the neonatal mouse was imaged after an 
intracardiac injection of radiolabeled antibody.  At near maximum gamma-radiation 
detection gain, there was no signal due to Ecgp96 in the brain, indicating no 
accumulation of antibody in the brain.  Therefore, Ecgp96 was concluded to not be 
accessible from the blood on the blood-brain barrier of neonatal mice.  In addition, after 
imaging a neonatal mouse brain, extra radioactive antibody was available, so the mother 
of the neonatal mouse was imaged to confirm via SPECT/CT that Ecgp96 is not 
accessible from the blood on adult mouse blood-brain barrier. At a near maximum 
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gamma-radiation detection gain, there was still no observable signal in the brain of the 
adult mouse.  
Confocal microscopy imaging was performed on sections of mouse brain resected 
a day after the mouse received a systemic dose of fluorescently labeled anti-Ecgp96 
antibody. This imaging modality only has an advantage over PET in that signal can be 
located at the tissue level.  Though PET is a sensitive method for determining if antibody 
accumulates in the bulk of the brain, it is possible that confocal microscopy could better 
detect signal from smaller quantities of labeled antibody when focused on a small section 
of tissue, such as an individual blood vessel.  No fluorescent signal was seen by confocal 
microscopy in the brain from the systemically injected anti-Ecgp96 antibody. Therefore, 
it was concluded that the Ecgp96 protein is not accessible from the blood on the surface 
of brain endothelial cells. 
To determine if Ecgp96 is associated with brain endothelial cells in-vivo as 
suggested by the work of Dr. Prasadarao, a normal mouse brain was resected, and tissue 
sections were stained with the antibody to Ecgp96 followed by a fluorophore-labeled 
secondary antibody for signal enhancement.  Specific Ecgp96 signal was seen in the 
vessels of the resulting images.  Therefore it was concluded that in normal mouse adult 
brain, Ecgp96 is expressed inside the endothelial cells, though not on the surface of the 
endothelial cells.  That Ecgp96 is not accessible from the blood negates its usefulness as a 
receptor target for the purpose of delivering nanoparticles from the blood into the brain.   
Confocal imaging of cultured HBMEC cells probed with antibody to Ecgp96 
suggested that Ecgp96 may be located on the surface of HBMEC cells in-vitro.  
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Incubating HBMEC cells with recombinant OmpA increased the expression of Ecgp96 
by twofold as measured by flow cytometry.  Because E. coli meningitis is a disease of 
neonatal infants, these cell culture results along with our in-vivo biodistribution studies 
suggest that neonatal blood-brain barrier endothelial cells in-vivo are stimulated by 
OmpA positive E. coli to express Ecgp96 on their surface when E. coli reach 
pathologically significant quantities in the blood. This may facilitate the interaction of E. 
coli OmpA with endothelial cell Ecgp96, which further facilitates the passage of the E. 
coli across the blood-brain barrier.  The exact mechanism of E. coli passage across the 
neonatal blood-brain barrier through this interaction is yet to be determined by an 
infectious disease lab.   
Methods and Experimental Results 
 
PET/CT Imaging 
  
Positron Emission Tomography (PET) is able to localize signal in three-
dimensional space from an injected radiolabeled biomolecule, and Computed 
Tomography generates a three-dimensional picture of the anatomy, which gives a 
reference for where the biomolecule localizes in-vivo. PET has several advantages to 
imaging biodistribution of biomolecules [13]: PET has a resolution of 3-10 mm and is 
capable of resolving signal at the organ level in mice, PET isotope 64Cu has a half-life of 
12.7 hours - excellent for radiolabeling and imaging over a 24 hour period, and coupling 
64Cu to antibody via chelator DOTA maintains 64Cu-antibody complexation to greater 
than 99% over a 24 hour period allowing for highly specific signal due to the location of 
the biomolecule of interest. PET/CT is a proven method for measuring real time 
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biodistribution of injected biomolecules [14], and was therefore employed here as the 
main method for investigating the presence of Ecgp96 on brain endothelium.  Antibody 
to Ecgp96 was labeled with 64Cu through chelating agent DOTA, and injected into a 
mouse to monitor the biodistribution of Ecgp96 (Figure 2.1). 
Figure 2.1:  Schematic of antibody to Ecgp96 attaching to Ecgp96.  Antibody labeled 
with 64Cu can be monitored in vivo by PET/CT.  Tissues in the body that contain Ecgp96 
accessible from the blood will be bound by the antibody, and the accumulation of the 
antibody in the tissues can be observed through PET. 
 
Conjugation of DOTA to Antibody  
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Both DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) 
conjugation to antibody and the evaluation of conjugation efficiency was performed as 
previously reported [15]. Briefly, DOTA-N-Hydroxysuccinimide (NHS)-ester was 
dissolved in dimethyl sulfoxide (DMSO) at 25 mg/ml.  IgG was buffer exchanged into 
0.1 M sodium phosphate/0.1 M sodium bicarbonate buffer (pH 8.6) at 2 mg/ml and 
reacted for 2 hours at room temperature with a 100 fold molar excess of DOTA-NHS-
ester. Unreacted DOTA and hydroxysuccinimide byproduct was removed by filtration 
through a 50 kDa MWCO filter, and IgG-DOTA resided in a final metal free PBS 
solution. All buffers were either made with metal-free water, or treated with Chelex to 
remove trace metals. NHS-esters bind non-specifically to exposed primary amines on the 
antibody, therefore it was expected that the antibody binding efficiency to its receptor (as 
measured by binding dissociation constant Kd) would be decreased. 
The degree of DOTA labeling was measured by determining the total DOTA 
content in solution and dividing by the total protein content in solution. A control 
antibody to be injected (normal mouse antibody) had 16 DOTA per IgG, and the antibody 
to Ecgp96 had 14 DOTA per IgG. Antibody content was measured using the Bradford 
method. DOTA content was measured by an Arsenazo III based spectrophotometric 
method. This is a simple non-radioactive method based on an exchange equilibrium of 
copper between arsenazo III reagent (red) and the copper complex of arsenazo III 
(purple) - absorbance changes measured at 580 nm. Previous studies have confirmed the 
degree of labeling values obtained by UV/Vis spectroscopy matches that found by 
radiolabeling [16]. Much like the Bradford method, a standard curve of DOTA 
concentrations allows for the calculation of the concentration of DOTA in the sample of 
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interest. Increasing DOTA ligand concentration at the beginning of the conjugation 
reaction lead to increased degree of labeling (Figure 2.2). 
 
Figure 2.2: Arsenazo assay on copper solutions mixed with DOTA-antibody (‘conjugated 
DOTA’) and free DOTA (‘unconjugated DOTA’).  DOTA-antibody was placed in 50 
kDa MWCO spin filters, and free DOTA that did not couple to antibody was removed by 
filtration.  As a control, identical concentrations of DOTA that were not reacted with 
antibody were also processed by spin filtration, and the retentate was also added to the 
Cu-arsenazo assay (‘unconjugated DOTA’ data series).  These data show that unreacted 
DOTA are efficiently removed by spin filtration, and that increasing the molar excess of 
DOTA during the reaction with antibody increases the degree of labeling of DOTA to 
antibody.    
 
The Ecgp96 antibody used for DOTA conjugation was generously supplied by Dr. 
Prasadarao. This antibody was produced in the late 1990’s, and gel electrophoresis with 
Comassie Blue staining of the IgG revealed there was a significant amount of antibody 
degradation over this time (data not shown). Size exclusion HPLC was performed to 
confirm the removal of these degradation productions during the 50 kDa MWCO 
filtration steps.  Note in Figure 2.3 the large peak at 28 minutes in the unconjugated 
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antibody due to degradation products of the antibody (peaks seen near 50 kDa on gel). 
This peak is greatly diminished in the ‘DOTA conjugated’ HPLC spectra. Though most 
of the 50 kDa fragment was filtered, some remained and was injected in the PET/CT 
imaging experiment. Also, as a confirmation of successful DOTA coupling to antibody, 
DOTA conjugated antibody had a retention time less than 20 minutes while the 
unconjugated antibody had a retention time greater than 20 minutes. This is consistent 
with a larger molecular weight of the DOTA conjugated antibody. 
 
Figure 2.3: HPLC spectra of Ecgp96 antibody conjugated to DOTA (left panel) and 
unmodified Ecgp96 antibody (right panel).  The antibody-DOTA conjugate has an elution 
time less than 20 minutes, while the unmodified antibody has an elution time greater than 
20 minutes.  Also, on first pass of the unmodified antibody through the HPLC, there is a 
significant amount of degradation products seen eluted near 28 minutes (the antibody was 
roughly ten years old at the time of this HPLC).  This predominant peak was not seen in 
HPLC spectra of antibody after purification by filtration. 
 
To assess the ability of the antibody to bind Ecgp96 post DOTA labeling, a 
binding study was performed using a Scatchard analysis followed by data modeling using 
a Langmuir Adsorption Isotherm. Scatchard analysis of receptor-ligand binding estimates 
both the dissociation constant, Kd, and the total number of receptor-binding sites, [⋆]o, in 
a given set of cells. Receptor-ligand binding and binding association constant Ka are 
given by the equations: 
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When the binding of the ligand to the receptor has reached equilibrium then 
[⋆]o = [⋆L] + [⋆]. Simple rearrangement leads to: 
 
which is a linear plot of slope –Ka and x-intercept of Ka[⋆]o. Therefore, the binding 
association constant Ka and total binding sites [⋆]o can be estimated from the linearized 
equation. Error propagation of the linearized data at low concentrations is large and 
distorts the actual parameter values. Untransformed data can be modeled in this case with 
a Langmuir adsorption isotherm, and parameters Ka and [⋆]o can be determined by 
performing a non-linear regression using a software package. The Langmuir adsorption 
isotherm is derived from an alternative rearrangement of the above relations and yields: 
 
MATlab function nlinfit, is a non-linear regression tool that was used to 
determine actual Ka and [⋆]o parameters.  Initial guesses are required by nlinfit, which 
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was initially provided by the Scatchard analysis, however a large range of reasonable 
initial values resulted in the same output (Figure 2.4 and Figure 2.5). 
The binding study was performed by flow cytometry.  HBMEC cells were 
detached from T75 flasks and fixed in BD Cytofix for 30 min at 4 oC.  Unmodified 
antibodies to Ecgp96 and DOTA labeled antibodies to Ecgp96 were labeled with 
AlexaFluor 488.  Increasing concentrations of these fluorophore labeled antibodies 
(denoted as “Ecgp96” and “Ecgp96-DOTA” respectively) were added to the cells.  An 
AlexaFluor labeled normal mouse antibody was used as a control. Cells were washed 
with 2% FBS in PBS and then analyzed by flow cytometry. Cells were appropriately 
gated based on forward and side scattering and bound antibody was measured by the 
geometric mean of the population fluorescent signal (Figure 2.5). 
The nonlinear fit shows that when antibody is conjugated to DOTA, there is a 
weak decrease in binding strength and a small increase in the total amount of binding. 
Decrease in binding affinity was expected since DOTA conjugation was site unspecific 
and could mask the antibody-docking site for Ecgp96.  The small increase in the total 
binding sites may be due to increased non-specific interaction of DOTA with HBMEC 
surface proteins, or due to errors in gating during data collection. Most importantly, this 
analysis shows the antibody to Ecgp96 does not appreciably lose its binding specificity or 
strength when coupled with DOTA. The normal mouse IgG control does not show 
binding to the HBMEC cells. 
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Figure 2.4:  Scatchard analysis of HBMEC binding study to both unmodified antibody to 
Ecgp96 (top panel) and DOTA labeled antibody to Ecgp96 (bottom panel). 
 
 
Figure 2.5: Geometric mean data generated from flow cytometry of HBMEC cells 
incubated with increasing concentrations of unmodified antibody to Ecgp96 and DOTA-
labeled antibody to Ecgp96. 
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Radiochemistry and Imaging  
Before injection and imaging, 64Cu was incubated with the DOTA conjugated 
antibodies at 43 oC in a citrate buffer for 45 minutes (both antibody to Ecgp96 and a 
normal mouse antibody control were labeled with 64Cu and injected into two separate 
mice).  Unchelated 64Cu was separated from the antibody by size exclusion using a 
Micro-bio-spin desalting column. Antibody labeling and purification were confirmed via 
instant thin layer chromatography (ITLC) using a Biodex tec-control 99mTc 
chromatograph strip. The IgG associated section 2 of the ITLC strip was separated from 
the free 64Cu associated section 1, the activity of each section measured in an activity 
counter, and the percent labeling (%LE) calculated: 
 
Post filtration, greater than 99.9% of activity was associated with the antibodies. 
Antibodies were immediately injected into C6 black adult mice (age 12-14 weeks) and 
two hour dynamic and 22 hour static images were taken. Images were taken at UCLA 
Crump Imaging Center under the direction of Dr. David Stout and Dr. Waldemar Ladno.  
Note there are no data for the mouse injected with normal mouse antibody at 22 hour as 
this mouse died overnight.  According to Dr. Ladno this rarely occurred and he had no 
explanation for the cause of death. 
Images were processed using Amide software, and the min and max threshold of 
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both the Ecgp96 probed and control mouse were set to the same levels.  After two hours 
post injection, there was no clear signal in the brain of either the Ecgp96 probed mouse 
(Figure 2.6) or the control mouse (Figure 2.7).   
 
Figure 2.6:  Transverse and coronal sections showing brain of a mouse injected with 
antibody against Ecgp96.  There is no clear PET signal from the antibody in the brain. 
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Figure 2.7:  Transverse and coronal sections showing brain of a mouse injected with a 
normal mouse antibody.  Again, there is no clear PET signal from the antibody in the 
brain. 
 
Though clearly visible signal was not seen in the brain from either injected mouse, 
it was possible that there was a minute amount of signal that was present, but not seen 
due to the threshold settings input into the Amide software.  Region of Interest (ROI) 
analysis in the Amide software was therefore employed to determine if accumulation of 
antibodies in the brain actually occurred.  In this analysis, a three dimensional ellipsoid 
region of interest was placed in the brain and also in the heart to monitor the signal that is 
due to antibody circulating in the blood (Figure 2.8).  The mean positron signal in the 
regions was tabulated over the dynamic scan period of two hours (Figure 2.9).   
The mean positron signal from the brains of both the control mouse and Ecgp96 
probed mouse closely follows the positron signal trend from the blood of both mice.  In 
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the Ecgp96 probed mouse, it appears there is more signal in the blood than the brain, 
however it must be noted that the mean positron intensity in the brain was very small, and 
slight variations in the maximum signal used to normalize this curve could shift the curve 
closer to the values observed in the blood.  Therefore, this analysis yielded negative 
results that the antibody significantly accumulated in the brain due to the presence of 
Ecgp96. 
 
Figure 2.8: Region of Interest Analysis.  Three-dimensional ellipsoid regions of interest 
were placed in the brain (left panel) and heart (right panel), and the mean positron signal 
in these regions was tabulated over the dynamic scan period of two hours.  
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Figure 2.9:  Dynamic ROI analysis.  Mean positron intensities were tabulated for both the 
Ecgp96 probed mouse (top panel) and control mouse (bottom panel). 
 
Though the PET scans demonstrated that Ecgp96 was likely not accessible to 
antibodies from the blood on the blood-brain barrier, an interesting observation was made 
in the eyes of the Ecgp96 probed mouse.  That is, there was a significantly higher 
positron signal in the eyes of the Ecgp96 probed mouse than the control mouse (Figure 
2.10).  It was unclear if this signal was due to antibody circulating in the blood, or if the 
antibody had associated with Ecgp96, perhaps at the blood-retina barrier.  Since the 
resolution of PET could not distinguish signal in retina from signal in blood, and since 
the ROI analysis was inconclusive, future plans for contrast enhancement MRI were 
made that could potentially spatially resolve these two regions (see next section). 
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Figure 2.10:  Two hours post injection, there was a significantly higher signal in the eyes 
of the Ecgp96 probed mouse (left panel) than the control mouse (right panel).  The 
increased signal in the eye from the Ecgp96 antibody was also observed at 22 hours. 
 
The PET scans did provide information that the majority of antibody (both 
antibody to Ecgp96 and normal mouse antibody) accumulated in the liver.  At two hours, 
a significant amount of both antibodies stuck to the liver, though it appears more of the 
antibody to Ecgp96 remained in circulation than the normal mouse antibody (Figure 
2.11).  
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Figure 2.11:  Normal mouse antibody (left panel) and antibody to Ecgp96 (right panel) 
two hours post injection.  Normal mouse antibody accumulates in the liver more than 
antibody to Ecgp96, which significantly remains in the heart/circulation two hours post 
injection. 
 
Conclusions for PET/CT imaging 
These images provided the first evidence that Ecgp96 was not on the blood-brain 
barrier in-vivo as it was not accessible from the blood by a systemically injected antibody.  
Though the PET/CT images were a basis for understanding the biodistribution of Ecgp96, 
it was decided additional imaging was needed using other imaging modalities to confirm 
Ecgp96 was not present on the surface of blood-brain barrier endothelial cells in-vivo.  
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Gd Contrast MRI Imaging 
 
Background - Searching for Ecgp96 with Increased Resolution in Eye  
By PET, there was a significantly higher positron signal in the eyes of the Ecgp96 
probed mouse than the control mouse, and it remained unclear if this signal was due to 
antibody circulating in the blood, or if the antibody had associated with Ecgp96 at the 
blood-retina barrier.  PET was not capable of producing images that clearly resolved 
signal from retina as opposed to the blood or surrounding fat and glands.  MRI has a 
spatial resolution much less than 1 mm, which is an advantage over PET; however, 
contrast enhanced MRI images require a concentration of imaging agents at least three 
orders of magnitude higher for MRI than for PET [13]. Giving up signal strength for 
resolution was necessary for in-vivo localization of the signal coming from the eye. 
Gadolinium (Gd) was selected as a contrast enhancing agent for MRI, which offers 
advantage over 64Cu in that radioactivity is not involved - eliminating the need for 
radioactivity protocols and special handling procedures involved with radioactivity.  
Previous studies have successfully utilized DOTA-Gd labeled globulins for tumor 
imaging [17], and Gd-transferrin labeled gold nanoparticles which were shown to 
accumulate in the brain [18].  
Gadolinium T1 Relaxation of Water  
Gd complexes with DOTA, and the same DOTA conjugated antibodies that were 
used in the PET/CT scans were also used for the MRI scans. DOTA-labeled antibodies 
were incubated with a solution of gadolinium chloride in acetate buffer for at least an 
hour, and unbound gadolinium was removed by spin filtration.  The arsenazo assay was 
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used to indirectly measure the amount of Gd chelated by DOTA (like copper, arsenazo 
also complexes with gadolinium [19]). To directly confirm Gd association with antibody, 
an NMR T1 relaxation study was employed.  Gd has been used as a contrast-enhancing 
image agent in MRI and has been shown to decrease the T1 relaxation time of water 
through the relation [20]: 
 
A standard curve was generated of T1 relaxation times of water with increasing 
concentrations of free gadolinium. Antibodies previously loaded with Gd were measured 
for their associated T1 relaxation values and the standard curve was used to calculate the 
amount of Gd associated with the antibodies.  Note this T1 relaxation quantification study 
may have limitations since Gd is complexed with DOTA and may not be fully accessible 
to water protons, which may effect the slope of equation (4). 
Measurements were taken on the 600 MHz FID at the NMR facilities at Caltech 
using 95% H2O and 5% D2O (Figure 2.12).  The arsenazo assay-based values of the Gd 
degree of labeling were consistent with the values obtained by the T1 relaxation study, 
providing both direct and indirect evidence that the antibodies were labeled with Gd 
through DOTA. 
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Figure 2.12.  Confirmation of gadolinium loading of antibody.  The T1 relaxation time of 
water increased with increasing concentration of free gadolinium (top panel).  The 
concentration of gadolinium bound to antibodies in solution measured indirectly by the 
arsenazo assay agreed with the values obtained by direct measurement through the T1 
relaxation study.  Note that goat antibody ‘Goat’ was used in lieu of antibody to Ecgp96 
as there was a limited amount of this valuable antibody left for injection.  As a control the 
T1 relaxation of water due to bovine serum albumin (BSA) not loaded with gadolinium 
was measured (no measurable increased T1 relaxation of water due to protein alone). 
 
Imaging  
One mouse was injected with 5 mg/kg of the Gd labeled Ecgp96 antibody and 
imaged 2 hours, 4 hours, and 24 hours post injection.  Figure 2.13 shows a comparison 
between the baseline cross-sectional image and the post-injection cross-sectional images. 
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There is little difference in the eye between the baseline image and the Gd contrast 
enhanced images and there is no clear accumulation of the Gd labeled antibody in the eye 
or brain. Unfortunately MRI proved to be an inadequate method for biodistribution 
studies - presumably due to the weak signal generated by T1 relaxation in comparison to 
the signal generated by 64Cu in PET. There was no signal seen in brain, consistent with 
the PET scan. 
 
Figure 2.13: Cross sections of brain and eyes from mouse MRI images.  Baseline, pre-
injection (left panel) image is no different than the images taken two, four, and 24 hours 
(left to right) post injection of gadolinium labeled antibody to Ecgp96.  There is no 
accumulated gadolinium signal in either the brain or the retina. 
 
Fluorescence Xenogen Imaging and Ecgp96 Biodistribution 
 
Motivation  
Confirmation of the biodistribution trend seen in the PET/CT scans could be 
relatively easily accomplished through use of a fluorescence Xenogen imaging system 
which is capable of detecting signal of a fluorophore labeled antibody in-vivo.  A 
capillary depletion method was used to determine amount of blood-brain barrier bound 
antibody that accumulated. 
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Fluorophore Conjugation  
Antibodies were labeled with a near infra-red AlexaFluor at an appropriate degree 
of labeling (2 fluorophores per IgG) for in-vivo imaging as specified by Invitrogen 
SAIVI antibody labeling kit. This kit was developed specifically for labeling antibodies 
with near-infrared fluorophores that emit light with high tissue penetration depths for the 
purpose of in-vivo imaging by fluorescence Xenogen spectrophotometry. 
Imaging  
Two mice were shaved for fluorescence Xenogen imaging. One of the mice was 
injected with 4 mg/kg of AlexaFluor 680 labeled antibody to Ecgp96 while the second 
mouse remained un-injected, acting as an auto-fluorescence control. 24 hours post 
injection the mice were anesthetized with isofluorane, their right atrium was opened, and 
10 ml of PBS were injected into the left ventricle. Confirmation of systemic perfusion 
was seen by the liver turning a whitish hue. PBS perfusion was employed to remove any 
antibody remaining in the blood that was not attached to the blood-brain barrier. After 
PBS perfusion, the brain, liver, heart, and eyes were resected and imaged simultaneously. 
During the analysis, the gain of the image processing software, Living Image, was 
adjusted so that the control organ was at the limit of detection for autofluorescence. The 
organ from the mouse injected with the fluorophore labeled antibody was then compared 
to see if there was increased fluorescence due to the accumulation of the injected 
antibody (Figure 2.14). 
There was no increase in fluorescence signal in the brain of the injected mouse 
over the autofluorescence measured from the control mouse brain.  This suggests that any 
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antibody in the brain was removed by the PBS perfusion and that no detectable antibody 
remained due to association with Ecgp96.  This is consistent with the PET/CT ROI 
analysis that showed there was no increased antibody signal in the brain over the signal 
that was present in the blood.   
There was a significant increase in the antibody-associated fluorescent signal of 
the liver in the injected mouse - consistent with the PET/CT scan.  There was no signal 
seen in the eyes from the fluorophore labeled antibody, which suggests that the signal 
seen in the PET/CT scan may have been from the blood, or from surrounding fat or 
glands.  There was increased signal due to the fluorophore-labeled antibody in the heart, 
which could possibly be from accumulation of the antibody there, or more likely from 
un-removed blood. 
Most important to the goals of this this work, fluorescence Xenogen imaging was 
the second imaging modality that demonstrated there was no signal in the brain due to 
accumulation of antibody bound to Ecgp96. This gave the second most definitive 
evidence that Ecgp96 was not accessible on the blood-brain barrier to antibody from the 
blood.   
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Figure 2.14: Fluorescence Xenogen Images of resected organs.  The ‘No Antibody’ 
organs in the left column were from a mouse not injected with antibody.  These organs 
were imaged directly next the organs that were resected from the mouse injected with the 
fluorophore labeled antibody to Ecgp96.  The images from these organs are in the 
‘Antibody Probed’ right column.  During analysis, the gain of the software was increased 
until the ‘No Antibody’ organs showed first signs of autofluorescence signal.  Any signal 
seen in the “Antibody Probed’ organs is above autofluorescence and due to the 
fluorophore labeled antibody that was injected and remained post PBS perfusion. 
 
SPECT/CT Imaging 
 
Motivation  
Ecgp96 was not on the surface of brain endothelial cells and accessible from the 
blood in adult mice.  However OmpA+ E. coli have been shown to breach the blood-
brain barrier through some Ecgp96-associated mechanism in-vivo when the studies were 
performed on three-day-old neonatal mice (personal communication with Dr. Prasadarao). 
This is consistent with E. coli meningitis being a disease of newly born infants. It was 
therefore hypothesized that Ecgp96 may be present on brain endothelial cells of neonatal 
mice, but not on the brain endothelial cells of adult mice. To test this hypothesis, a new 
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PET/CT biodistribution study for Ecgp96 in neonatal mice was proposed. 
Injecting antibody into neonatal mice for the PET/CT studies is difficult as three-
day-old mouse veins are small. To systemically administer agents into neonatal mice, Dr. 
Prasadarao and others [10] have used intracardiac injections.  The PET/CT facilities at 
UCLA neither worked with neonatal mice nor performed intracardiac injections, 
therefore the proposed imaging studies could not be performed using PET/CT at UCLA.  
Dr. Prasadarao had experience with intracardiac injections and had approved protocols 
for working with neonatal mice at CHLA.  Dr. Rex Moats at the CHLA Small Animal 
Imaging Research Center (SAIRC) had facilities that were willing to work with neonatal 
mice and image them by SPECT/CT.  Therefore the proposed neonatal mouse 
experiments would be carried out using SPECT/CT as opposed to PET/CT. 
Radiolabeling and Imaging  
DOTA conjugation to IgG and radiolabeling along with confirmatory studies were 
performed with the same protocols used in preparation for PET/CT imaging, except that 
111In was used as the radioisotope for SPECT imaging in lieu of 64Cu.  111In is a gamma 
emitter with a half-life of just over two days which readily complexes with DOTA and is 
detectable by SPECT.  Biodistribution studies of DOTA-111In conjugates of different 
proteins have been previously performed by SPECT [21, 22]. 
An estimated 3 mg/kg of 111In labeled antibody to Ecgp96 was injected into a C6 
black adult mouse and imaged 24 hours post injection. A lead shield was placed around 
the body of the mouse to reduce signal from the torso allowing increased gain from brain 
without signal washout from non-brain regions such as the heart and liver. No signal 
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from the brain was observed at the maximum gain, confirming again that antibody to 
Ecgp96 does not accumulate in the brain of adult mice. 
 
Figure 2.15: SPECT/CT images of Ecgp96 probed adult brain.  The signal seen near the 
tip of the nose was taken when the gamma detector gain was set near saturation and is 
considered to be non-specific.  The lead shield seen near the base of the sagittal and 
coronal sections eliminated signal from the heart and lung, and allowed imaging with 
high gamma-detection gain without signal washout in the brain from these organs.  There 
was no detectable signal from the brain of the mouse before the gamma detector gain 
exceeded total signal saturation. 
 
An estimated 3 mg/kg of 111In labeled antibody to Ecgp96 was injected into a 
three-day old C6 black mouse and imaged 24 hours post injection. A lead shield was also 
placed around the body of the pup, again to reduce signal from the torso allowing 
increased gain from brain without signal washout from non-brain regions. Unfortunately, 
the technician taking the SPECT/CT scan moved the pup such that the head was not in 
the same position during the CT scan that it was in during the SPECT scan. It appears 
however that the SPECT signal is located near where the nose of the pup would have 
been had it not fallen out of the anesthesia tube (similar signal seen in the adult mouse 
brain). For the SPECT signal to be from brain, the head would have been completely 
inside the anesthesia tube, therefore it was assumed that the signal was not from the brain. 
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Figure 2.16: SPECT/CT images of Ecgp96 probed neonatal mouse brain.  Like the adult 
mouse, the signal seen near the tip of the nose was taken when the gamma detector gain 
was set near saturation.  There was no observable gamma signal in the brain of the 
neonatal mouse. 
 
 These results demonstrate that in normal neonatal mice there is no accumulation 
of antibody to Ecgp96 in the brain.  Ecgp96 is therefore not present on the blood-brain 
barrier and accessible from the blood in three-day old mice. 
Confocal Microscopy 
 
Motivation  
Ecgp96 was not detected on the blood-brain barrier in-vivo, however this did not 
conclusively rule out the possibility that Ecgp96 was not located within the endothelial 
cells in-vivo. As a final study to see if any signal could be detected in or on brain 
endothelium from antibody directed against Ecgp96, confocal microscopy was performed. 
Confocal microscopy has been validated as a method for detecting antibodies directed 
against blood-brain barrier receptors for up to 24 hours [23, 24]. Confocal may have 
advantages over PET and SPECT in that the confocal microscope can focus in on a small 
region of tissue possibly with a much higher sensitivity than PET or SPECT for local 
signal from the injected antibody. 
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Imaging  
1.5 mg/kg of AlexaFluor 488 labeled antibody directed against Ecgp96 was 
injected into a six-week-old A/J mouse. 24 hours post injection the mouse was perfused 
with 40 ml PBS at 2 ml per min. The brain was resected, paraffin embedded, and 
mounted for confocal imaging. A second mouse was injected with 3.5 mg/kg of 
AlexaFluor 488 labeled antibody (normal mouse IgG from Santa Cruz Biotech) and 
similarly processed. No antibody signal was seen in the mouse antibody negative control 
or from sections taken from the Ecgp96 antibody injected mouse (Figure 2.17).  Signal 
from the antibody was seen in liver consistent with the PET/CT and Xenogen 
experiments.   
To determine if Ecgp96 was located inside the endothelial cells of the blood-brain 
barrier, a normal mouse brain was resected, and paraffin embedded tissue sections were 
stained with the antibody to Ecgp96 followed by a secondary antibody for signal 
enhancement.  Signal from the Ecgp96 antibody was clearly observed from the blood 
vessels within this tissue section (Figure 2.17).  Ecgp96 therefore exists in the blood 
vessels, however it is not accessible from the blood. 
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Figure 2.17: Confocal microscopy of mouse brain sections.  Confocal images of the brain 
from the mouse injected with AlexaFluor labeled antibody to Ecgp96 show no specific 
signal above the background auto-fluorescence (left panel).  Brains that were first 
resected followed by tissue staining with antibody to Ecgp96 followed by a fluorophore 
labeled secondary antibody show clear signal from Ecgp96 in the blood vessels (right 
panel). 
 
In-vivo Studies Conclusion 
 
 In conclusion, the accumulated results from PET/CT, SPECT/CT, Fluorescence 
Xenogen imaging, MRI, and confocal microscopy indicate that Ecgp96 is located within 
the endothelial cells of the blood-brain barrier, however Ecgp96 is not accessible to 
antibodies from the blood.  Confocal microscopy of sectioned brain tissue demonstrated 
that Ecgp96 did reside within the endothelial cells.  PET/CT imaging demonstrated that 
there was no accumulation of antibodies to Ecgp96 in the brain, and ROI analysis 
confirmed that there was no significant accumulation of antibody in the brain above the 
signal observed from the blood. 
 SPECT/CT based biodistribution studies on neonatal mice demonstrated that 
Ecgp96 was also not accessible from the blood on the blood-brain barrier endothelial 
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cells of neonatal mice.  Most importantly it was shown that Ecgp96 cannot be accessed 
from the blood on blood-brain barrier endothelial cells in adult mice and therefore it 
cannot serve as a target receptor for receptor-mediated transcytosis of nanoparticles 
across the blood-brain barrier. 
In-vitro Studies of Ecgp96 
 
Ecgp96 was found to be inaccessible from the blood on the blood-brain barrier in-
vivo, however there is still evidence that Ecgp96 is expressed on the surface of brain 
endothelial cells in-vitro.  HBMEC cells provided by Dr. Prasadarao were used in the 
binding studies of the DOTA conjugated antibody to Ecgp96, suggesting that the Ecgp96 
is surface expressed on these cells, at least when they are grown in culture.  The 
following in-vitro experiments were performed to help confirm that Ecgp96 was 
expressed on the surface of the HBMEC cell line and that Ecgp96 expression is increased 
in these cells when in the presence of E. coli-associated protein OmpA.  
Confocal Microscopy of HBMEC Visualizing Surface Expression of Ecgp96  
Ecgp96 has been shown to be surface expressed on HBMEC in-vitro through 
imaging of HBMEC cells incubated with E. coli and also through immunocytochemical 
staining and flow cytometry experiments [2-4, 11]. Since Ecgp96 is mainly an 
endoplasmic reticulum associated protein, it is necessary to confirm that the signal seen 
in the flow cytometry experiments is in fact associated with the membrane surface (and 
not due to endoplasmic reticulum-associated signal from cells with compromised 
membrane associated with cell processing). Confocal microscopy has been used in the 
literature to confirm surface expression of proteins [25, 26].  
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Figure 2.18: z-stack of confocal images of HBMEC cells with staining for actin (red), 
Ecgp96 (green), and cell nuclei (blue).  Images begin at the glass slide (a) and move up 
by increments of 0.4 um.  Passing through the bulk of the cell body near the glass slide it 
appears there is little to no signal from Ecgp96 colocalized with the actin signal (panels 
a-c) indicating there is likely no significant intracellular signal.  There is clear Ecgp96 
near the periphery of the cell (especially in panels c-h) indicating a strong possibility that 
Ecgp96 is located on the surface of the cell. 
 
Signal for Ecgp96 appears to be on the surface of the cells, though it cannot be 
directly proven from these images (Figure 2.18). The optimal pinhole size (for the 488 
nm laser on the LSM 510 Meta) collects light from 1 μm axially, and HBMEC cells were 
seen to be only 1.3 μm thick. The signal from the flattened region of the cells therefore 
could not be completely resolved through the z-axis to confirm signal was cell surface 
associated. Though signal around the area of the nucleus could be from membrane, it 
could also be from within the cell, in the perinuclear region of the cytoplasm where 
endoplasmic reticulum usually resides. The lateral resolution was only about 0.3 μm, and 
the signal from the nucleus (blue) is continuous with the signal from Ecgp96 (green). 
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This analysis shows that for thin cells (such as endothelial cells), it is difficult to 
determine surface expression by confocal microscopy. For cells much thicker than 1 μm, 
it would be easy to see a perimeter of surface-associated signal. 
OmpA Induced Surface Expression of Ecgp96 
Monitoring Ecgp96 surface expression of HBMEC has often involved incubation 
with OmpA positive E. coli [3, 11]. Our lab does not work with OmpA positive E. coli, 
and we have had difficulty observing Ecgp96 via flow cytometry without the HBMEC 
exposure to OmpA positive E. coli.   It was therefore hypothesized that Ecgp96 surface 
expression on HBMEC cells is increased by some factor on the E. coli stimulating 
Ecgp96 delivery to the HBMEC cell surface.  Since it has been shown there is little to no 
invasion of OmpA negative E. coli in HBMEC, but there is adhesion and invasion of 
OmpA positive E. coli into HBMEC, it was likely that OmpA was the E. coli protein 
responsible for the proposed mechanism of increased Ecgp96 surface expression. To 
independently confirm that OmpA may be in fact stimulating the surface expression of 
Ecgp96 on HBMEC cells (as opposed to other possibly confounding factors associated 
with E. coli), purified recombinant OmpA was purchased from a third party (Genway), 
and a flow cytometry based binding experiment was performed with OmpA pre-
incubated cells. 
One flask of HBMEC cells was incubated with 10 nM OmpA for one hour. Three 
flasks were placed on ice for 20 minutes (remaining on ice for the remainder of 
processing), and then cells were removed by scraping. The cells were then incubated in 
increasing concentrations of an Abcam GRP94 antibody for one hour. The cells were 
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washed and all cells were incubated in a 1:500 goat-anti-rabbit-AF488 antibody for 30 
minutes. The cells were again washed and analyzed by flow cytometry. All forward and 
side scattering gating and voltage gain settings were set on the first measured sample and 
unchanged afterward. Primary antibody to intracellular antigen (bcl-2) acted as an isotype 
control that should not bind to the cell surface and that would serve as a control to 
confirm the cell membrane remained un-permeabilized during cell processing.  Scatchard 
analysis was performed to determine the initial Ka and [⋆]o guesses for nlinfit (Scatchard 
values are in parentheses in the table below). 
 
Table 2.1.  Binding strengths of GRP94 antibody to HBMEC associated Ecgp96 (Ka) and 
modeled total number of Ecgp96 binding sites on HBMEC cells [⋆]o.  
 
These values suggest that by adding OmpA, the total number of GRP94 antibody 
binding sites significantly increases on HBMEC cells (very similar to the results reported 
by Mittal et al [11]). Also this data suggests that upon addition of OmpA, the binding 
affinity of Ecgp96 to the GRP94 antibody decreases, which is likely due to Ecgp96-
OmpA interactions that reduce the antibody docking sites on Ecgp96. The isotype control 
showed almost no specific binding to the cells, however there was a small amount that 
did bind indicating there may have been some cell death and membrane permeabilization 
during processing for flow cytometry. Inserting [⋆]o and Ka into a Langmuir Isotherm, 
the data can be well fit (Figure 2.19). Error bars indicate one standard deviation of the 
gated events. 
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Figure 2.19:  Flow Cytometry of HBMEC cells.  Cells incubated with OmpA have 
increased expression of Ecgp96 receptor on their surface. 
 
These results are significant since they show that the Ecgp96 receptor is more 
highly expressed on the surface of HBMEC cells when they are exposed to OmpA. Since 
OmpA increases the surface expression of Ecgp96 on the HBMECs in-vitro it may be 
that OmpA is necessary to stimulate the expression of Ecgp96 on the surface of brain 
endothelial cells in-vivo. Administration of OmpA expressing E. coli in-vivo may 
therefore stimulate the surface expression of Ecgp96 on brain endothelium.  
Since E. coli meningitis is a disease of neonates and is predominantly due to 
OmpA positive E. coli, one interpretation of Dr. Prasadarao’s studies in light of our in-
vivo and in-vitro results is that neonatal (but not adult) blood-brain barrier endothelial 
cells in-vivo are stimulated by OmpA positive E. coli to express Ecgp96 on their surface 
at pathologically significant quantities. This may facilitate the interaction of OmpA with 
Ecgp96, and subsequently some mechanism occurs that allows the passage of the E. coli 
across the blood-brain barrier. 
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In-vitro Studies Conclusion 
Studies of HBMEC cells in culture demonstrated that the expression of Ecgp96 on 
HBMEC cells in culture is directly related to the presence of the E. coli related protein, 
OmpA, without the presence of the E. coli itself.  Since E. coli has been shown to 
infiltrate the central nervous system of neonatal mice, and that E. coli meningitis is 
predominantly a disease of neonatal infants, it was concluded that E. coli and related 
OmpA are likely necessary for the expression of Ecgp96 on the surface of blood-brain 
endothelial cells in neonatal mice.  This would be consistent with OmpA positive E. coli 
as a stressor that causes the loss of Ecgp96 ER retention signal KDEL (which has been 
reported for cells under stress [3, 16]) and subsequent Ecgp96 transport to and 
accumulation at the site of OmpA positive E. coli binding. 
Summary and Discussion 
 
Our studies have demonstrated that Ecgp96 cannot be accessed at the blood-brain 
barrier from the blood in-vivo in adult and neonatal mice under normal, non-pathological 
conditions. These results conclusively demonstrate Ecgp96 cannot be used as a receptor 
at the blood-brain barrier for receptor-mediated nanoparticle delivery to the brain.  These 
results also help direct future work to be performed by infectious disease labs to further 
understand the mechanism of E. coli mediated neonatal meningitis, and in particular how 
Ecgp96 is involved in this process.  The in-vivo results from this work suggest there must 
be an alternative mechanism that explains how OmpA positive E. coli are more able to 
penetrate the blood-brain barrier than OmpA negative E. coli.  In particular future work is 
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needed with focus on how OmpA may be necessary for the expression of Ecgp96 on the 
surface of blood-brain barrier endothelial cells in neonatal mice when E. coli are present 
in the blood at pathologic levels. 
For the purposes of our lab and targeted drug delivery, it is undesirable to target a 
receptor that cannot be visualized without stimulation by an E. coli meningitis-associated 
protein such as OmpA. Though academically interesting, it would be clinically 
impractical to develop a therapeutic that would either require a pre-injection of OmpA in 
humans or incorporate a possibly harmful OmpA molecule on the nanoparticle surface to 
make the nanoparticle capable of crossing the blood-brain barrier. A more practical 
solution to delivering nanoparticles into the brain would be to target a blood-brain barrier 
receptor that is widely accepted to be on blood-brain barrier endothelial cells and is 
associated with receptor mediated transcytosis. The transferrin receptor has both of these 
advantages and already has a clinically approved recombinant protein for human 
application that can be used for receptor targeting. The transferrin receptor is therefore 
much better suited for investigation than Ecgp96. 
  
  
62 
References 
 
1. National Center for Health Statistics. NCHS Data Brief 90, Number 88, March 
2012. 1–8 (2012). 
2. Prasadarao, N., Wass, C. & Kim, K. Identification and characterization of S-
fimbria-binding sialoglycoproteins on brain microvascular endothelial cells. 
Infection and Immunity 65, 2852–2860 (1997). 
3. Prasadarao, N. Identification of Escherichia coli outer membrane protein A 
receptor on human brain microvascular endothelial cells. Infection and Immunity 
70, 4556 (2002). 
4. Prasadarao, N. et al. Cloning and expression of the Escherichia coli K1 outer 
membrane protein A receptor, a gp96 homologue. Infection and Immunity 71, 1680 
(2003). 
5. Csermely, P., Schnaider, T., Soti, C., Prohaszka, Z. & Nardai, G. The 90-kDa 
molecular chaperone family: Structure, function, and clinical applications. A 
comprehensive review. Pharmacol Therapeut 79, 129–168 (1998). 
6. Robert, J., Menoret, A. & Cohen, N. Cell surface expression of the endoplasmic 
reticular heat shock protein gp96 is phylogenetically conserved. J Immunol 163, 
4133–4139 (1999). 
7. Kang, S. H. & Welch, W. J. Characterization and purification of the 94-kDa 
gluocose-regulated protein. J Biol Chem 266, 5643–5649 (1991). 
8. Altmeyer, A. et al. Tumor-specific cell surface expression of the -KDEL 
containing, endoplasmic reticular heat shock protein gp96. Int J Cancer 69, 340–
349 (1996). 
  
63 
9. Ahmed Khan, N. Outer membrane protein A and cytotoxic necrotizing factor-1 use 
diverse signaling mechanisms for Escherichia coli K1 invasion of human brain 
microvascular endothelial cells. Microbial Pathogenesis 35, 35–42 (2003). 
10. Wang, Y. & Kim, K. S. Role of OmpA and IbeB in Escherichia coli K1 invasion 
of brain microvascular endothelial cells in vitro and in vivo. Pediatr Res 51, 559–
563 (2002). 
11. Mittal, R. & Prasadarao, N. V. Nitric oxide/cGMP signalling induces Escherichia 
coli K1 receptor expression and modulates the permeability in human brain 
endothelial cell monolayers during invasion. Cellular Microbiology 12, 67–83 
(2010). 
12. Nag, S., Kapadia, A. & Stewart, D. J. Review: Molecular pathogenesis of blood-
brain barrier breakdown in acute brain injury. Neuropathology and Applied 
Neurobiology 37, 3–23 (2011). 
13. Smith, S. Molecular imaging with copper-64. Journal of Inorganic Biochemistry 
98, 1874–1901 (2004). 
14. Bartlett, D. W., Su, H., Hildebrandt, I. J., Weber, W. A. & Davis, M. E. Impact of 
tumor-specific targeting on the biodistribution and efficacy of siRNA 
nanoparticles measured by multimodality in vivo imaging. P Natl Acad Sci Usa 
104, 15549–15554 (2007). 
15. Al-Ejeh, F., Darby, J. M., Thierry, B. & Brown, M. P. A simplified suite of 
methods to evaluate chelator conjugation of antibodies: effects on hydrodynamic 
radius and biodistribution. Nuclear Medicine and Biology 36, 395–402 (2009). 
16. Brady, E. D., Chong, H. S., Milenic, D. E. & Brechbiel, M. W. Development of a 
  
64 
spectroscopic assay for bifunctional ligand-protein conjugates based on copper. 
Nuclear Medicine and Biology 31, 795–802 (2004). 
17. Tan, M., Wu, X., Jeong, E.-K., Chen, Q. & Lu, Z.-R. Peptide-targeted 
nanoglobular Gd-DOTA monoamide conjugates for magnetic resonance cancer 
molecular imaging. Biomacromolecules 11, 754–761 (2010). 
18. Korkusuz, H. et al. Transferrin-coated gadolinium nanoparticles as MRI contrast 
agent. Mol Imaging Biol (2012). doi:10.1007/s11307-012-0579-6 
19. Nagaraja, T. N. et al. Application of arsenazo III in the preparation and 
characterization of an albumin-linked, gadolinium-based macromolecular 
magnetic resonance contrast agent. J Neurosci Methods 157, 238–245 (2006). 
20. Curtet, C. et al. Selective modification of NMR relaxation time in human 
colorectal carcinoma by using gadolinium-diethylenetriaminepentaacetic acid 
conjugated with monoclonal antibody 19-9. P Natl Acad Sci Usa 83, 4277–4281 
(1986). 
21. Virgolini, I. et al. Indium-111-DOTA-lanreotide: Biodistribution, safety and 
radiation absorbed dose in tumor patients. Journal of Nuclear Medicine 39, 1928–
1936 (1998). 
22. Jalilian, A. Preparation, quality control and biodistribution studies of two [111In]-
rituximab immunoconjugates. Sci Pharm 76, 151–170 (2008). 
23. Paris-Robidas, S., Emond, V., Tremblay, C., Soulet, D. & Calon, F. In vivo 
labeling of brain capillary endothelial cells after intravenous injection of 
monoclonal antibodies targeting the transferrin receptor. Mol. Pharmacol. 80, 32–
39 (2011). 
  
65 
24. Yu, Y. J. et al. Boosting brain uptake of a therapeutic antibody by reducing its 
affinity for a transcytosis target. Science Translational Medicine 3, 1–8 (2011). 
25. Jiang, W., Kim, B. Y. S., Rutka, J. T. & Chan, W. C. W. Nanoparticle-mediated 
cellular response is size-dependent. Nature Nanotech 3, 145–150 (2008). 
26. Na, X., Kim, H., Moyer, M. P., Pothoulakis, C. & Lamont, J. T. gp96 is a human 
colonocyte plasma membrane binding protein for Clostridium difficile toxin A. 
Infection and Immunity 76, 2862–2871 (2008). 
  
  
66 
 
Chapter 3:  Formulation and Characterization of 
Transferrin Containing Gold Nanoparticles* 
Introduction 
 
 Once it was established Ecgp96 was not a good candidate target receptor at the 
blood-brain barrier for achieving receptor mediated transcytosis, a decision was made to 
attempt to deliver nanoparticles to the brain through the transferrin receptor.  The 
transferrin receptor is responsible for internalizing iron carrying protein transferrin, it is 
expressed throughout the body, it is well accepted to exist on the blood-brain barrier [1], 
and it has been widely studied for its potential ability to deliver entities across the blood-
brain barrier (historically by monoclonal antibody OX26) [2].  Usage of transferrin 
receptor enables further investigations of different nanoparticle designs that may cross 
the blood-brain barrier by receptor-mediated transcytosis.   A well-defined set of 
nanoparticle designs of varying size and transferrin content are formulated and 
characterized here in order to carry out meaningful in-vivo experiments.   
  The objective of this work was to investigate whether the blood-brain barrier 
transcytosis behavior of transferrin-targeted nanoparticles was similar to the blood-brain 
barrier transcytosis behavior of antibodies reported by Yu et al. [3] in the sense that the 
avidity (or nanoparticle effective binding strength to multiple receptors) must be 
appropriately modulated in order to allow receptor binding from the blood, transcytosis 
across the blood-brain barrier, and release from the receptors into the brain parenchyma. 
                                                
* Excerpts of this chapter are reproduced with permission from “Transcytosis and brain uptake of 
transferrin-containing nanoparticles by tuning avidity to transferrin receptor.”  Wiley, D. T., Webster, P., 
Gale, A., & Davis, M. E. Proc. Natl. Acad. Sci. USA. (2013). 
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Our expectation was that in order to effectively undergo blood-brain barrier transcytosis 
the nanoparticles would need proper avidity, size and surface charge.  Designs of varying 
nanoparticle size and avidity with fixed zeta potentials are studied here. 
  Our research group has been involved in translating two nanoparticles from the 
laboratory into clinical trials [4-5].  These nanoparticles are below 100 nm in size for 
many reasons including their ability to move through tissues.  Here, we restrict our 
investigations to nanoparticles in this size range.  After the completion of our 
experimental studies, it was reported that nanoparticles in the sub-100 nm range can, in 
fact, move through brain tissue [6].  Additionally, it is known that nanoparticle zeta 
potentials that are slightly negative to near neutral are desirable, as highly negatively and 
positively charged nanoparticles are known to: (i) disrupt the BBB [7], (ii) facilitate 
formation of protein coronas that may mask or alter the function of the targeting ligand 
[8], and (iii) elicit unwanted immune responses and faster blood clearances via increased 
uptake through the mononuclear phagocyte system (MPS) [9]. 
  It is well known that the avidity and receptor selectivity of targeted nanoparticles 
can be tuned by the choice of targeting ligand and its number density (multivalent 
nanoparticles can engage multiple cell surface receptors at the same time) [10, 11].  
When an individual targeting ligand is conjugated to a nanoparticle, the affinity of the 
ligand to the receptor is reduced. However, if the receptor density is such that multiple 
targeting ligands on the nanoparticle can simultaneously bind to the receptors, then the 
targeted nanoparticle avidity [12] and selectivity [11] can be increased. These effects 
have been illustrated in several investigations; for example, Choi et al. reported the 
interactions of transferrin-containing gold nanoparticles on both cancer cells in-vitro and 
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tumors in-vivo in mice [12].  These authors showed that the animal whole body 
biodistribution of transferrin containing gold nanoparticles of ca. 70 nm diameter was 
independent of the transferrin content, but that the amount of nanoparticles localizing in 
the cancer cells of solid tumors 24 hours after injection increased with increasing 
transferrin content. Thus, the targeting ligand acts as a cell entrance facilitator rather than 
altering the biodistribution of the nanoparticles. This effect is now being reported for a 
number of different types of targeted nanoparticles.  
 Transferrin-containing gold nanoparticles were chosen as a model nanoparticle 
system to engage the transferrin receptor at the blood-brain barrier.  Human transferrin 
has already been used as a targeting agent on nanoparticles in human clinical trials [4, 
13], and it is a recognized ligand for the well established transferrin receptor at the blood-
brain barrier.   Human transferrin that is fully loaded with iron (holo-transferrin) binds 
strongly to transferrin receptor (Kd = 1-10 nM) [14], and, after vesicle acidification and 
iron release, the subsequent apo-transferrin has a reduced binding strength to transferrin 
receptor (Kd > 700 nM) [14] at physiologic pH.  Mouse transferrin was not employed for 
reasons provided below. 
  Gold nanoparticles were chosen for this work due to their ease of synthesis, 
surface modification through reactions with thiol groups, quantification by inductively 
coupled plasma–mass spectroscopy (ICP-MS), and imaging by TEM. Additionally, we 
found that gold nanoparticles are convenient for studies of the blood-brain barrier 
because they can be visualized inside and outside the vasculature by light microscopy 
through silver enhancement.  The silver enhancement of gold nanoparticles is a highly 
sensitive detection technique, and has been used to detect zeptomolar concentrations of 
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nanoparticles in immune assays [15]. Furthermore, silver enhancement has been used to 
visualize gold nanoparticles in kidney and tumor through light microscopy [16, 17]. 
Experimental Results 
 
  Transferrin was coupled to gold nanoparticles through an NHS-PEG5k-OPSS 
linker, where the NHS-ester reacts with transferrin through primary amines on lysine 
groups (preferred PEG coupling method to transferrin [18]), and OPSS reacts with gold 
surfaces through gold-thiol dative bonding (Figure 3.1).  Mono-PEGylated transferrin 
was highly purified before coupling to the gold nanoparticles (Figure 3.2), as di-
PEGylated transferrin can cause a small degree of particle aggregation.  Gold cores of 
increasing sizes (5 nm, 20 nm, and 50 nm) were reacted with increasing amounts of Tf-
PEG5k-OPSS (transferrin – Tf), and afterward, methoxy-PEG5k-SH (PEGylation) was 
added to the nanoparticle surface to increase nanoparticle stability in high ionic solutions 
such as blood. Attempts to use mouse transferrin for nanoparticle assembly failed. For 
unknown reasons, mouse transferrin does not appear to be as stable as human transferrin 
to these types of physical and chemical manipulations. 
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Figure 3.1: Representation of targeted nanoparticle assembly process (n ~ 120, PEG MW 
of 5,000 Da). 
 
 
 
Figure 3.2.  a, High Pressure Liquid Chromatography (HPLC) data with an impure 
monoPEGylated fraction eluting at the second peak.  All unconjugated transferrin eluted 
in the first peak.  b, Hydrophobic Interaction Chromatography (HIC) performed post 
HPLC with a pure monoPEGylated fraction eluting from the first peak.  c, Matrix 
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Assisted Laser Desorption-Ionization Time of Flight (MALDI-TOF) Mass Spectroscopy 
demonstrating a monoPEGylated fraction was obtained (MW = 83 kDa); unPEGylated 
transferrin had a MALDI-TOF peak at 78 kDa. 
 
  Nanoparticle sizes were measured with dynamic light scattering (DLS) and 
Nanoparticle Tracking Analysis (NTA) technologies.  NTA methods allow direct 
visualization of individual nanoparticles and can provide nanoparticle size distributions 
within a sample.  All NTA sizes listed in Table 3.1 are from unimodal size distributions, 
indicating a single population of similarly sized nanoparticles. Unfortunately, the smaller 
sized nanoparticles cannot be detected by this method.  Since the NTA size distributions 
were unimodal, DLS was employed, and the sizes listed in Table 3.1.  For those 
nanoparticles measured by both NTA and DLS methods, the sizes were essentially the 
same. All the nanoparticles synthesized had zeta potentials between  -15 mV and -5 mV, 
when measured in 1.5 mM KCl (Table 3.1).  Zeta potential distributions were measured 
for the ca. 80 nm nanoparticles using NTA methods. The full width at half maximum 
(FWHM) values obtained from the zeta potential distributions did not vary with 
transferrin content. These data would be consistent with a similar Poisson-type 
distribution of transferrin over the nanoparticle population for each formulation. 
  Transferrin content on the nanoparticles was directly measured by: (i) apo-Tf-
PEG-OPSS chelation of 64Cu, (ii) nanoparticle formulation with 64Cu-Tf-PEG-OPSS, and 
(iii) measurement of nanoparticle associated gamma activity (Cu chelation method 
modified from [19]).  The average transferrin contents of some of the nanoparticle 
formulations are listed in Table 3.1. The nanoparticles were formulated so that there was 
a wide range of transferrin on the surface of the nanoparticles; each size having a 
formulation with very little transferrin, and a formulation approaching the maximum 
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number of possible transferrin molecules on each particle.  The theoretical maxim density 
of transferrin on the surface of the nanoparticle was estimated based on the total surface 
area of the particle (from the surface area of a sphere), and an estimate of the amount of 
surface each transferrin molecule could cover (hydrodynamic radius approximately 4 nm 
per transferrin [20]).   Note that as the attempted loading of transferrin increased (amount 
listed in column one of Table 1), the fraction of transferrin that actually was on the 
nanoparticle decreased, most likely due to steric crowding. 
  More critical than the precise number of transferrin on each nanoparticle 
formulation is the nanoparticle avidity and how it changes with transferrin content. Yu et 
al. performed competitive binding assays with mouse transferrin receptor in order to 
provide a relative ranking of the antibodies used in their study [3], while Friden et al. 
used purified human transferrin receptor and the human K562 cell line to measure 
transferrin and antibody binding [21].  Here, in order to provide a relative ranking of 
nanoparticle avidity, binding isotherms were obtained using Neuro2A cells as a model 
cell type with mouse transferrin receptor (Figure 3.3, Kd values listed in Table 3.1). The 
Kd values have an inverse relationship with transferrin content (Figure 3.4a).  There is a 
clear increase in avidity with transferrin content within each formulation size (Figure 
3.4b). Within the limited number of nanoparticles used in this study, it appears that there 
is a weak effect of size on avidity (Figure 3.4b).  Previous reports that included much 
smaller nanoparticle sizes similarly observed that increasing the size and antibody 
content of antibody-coated nanoparticles increased their avidity to cell surface receptors 
[22]. 
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Figure 3.3:  Binding isotherm data for each nanoparticle formulation on Neuro2A cells.  
The model curves are based on Langmuir isotherms, where Kd and Bmax values were 
numerically determined by Matlab nlinfit. 
 
 
Figure 3.4: Binding data of gold nanoparticle formulations on Neuro2A cells.  a, Effects 
of nanoparticle transferrin content on the binding dissociation constant of the 
nanoparticle to Neuro2A transferrin receptors.  b, Effects of nanoparticle size and 
transferrin content on binding dissociation constant of the nanoparticle to Neuro2A 
transferrin receptors. 
 
a b
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Table 3.1.  Nanoparticle formulations and characterizations. 
 
Methods 
 
Tf-PEG-OPSS Synthesis. Human holo-transferrin (Sigma, 100 mg, 2 mg/ml) was added 
to 8 molar excess NHS-PEG5k-OPSS (Creative PEGworks) in a 10 mM sodium 
phosphate buffer, pH 9.0.  The reaction proceeded for 90 minutes under gentle rocking at 
room temperature.  Excess PEG was removed and the transferrin was concentrated in a 
50 kDa MWCO centrifugal filter (Amicon, Millipore) after which the monoPEGylated 
fraction was separated by HPLC (1200 series, Agilent, using two TOSOH TSK gel 
G3000swxl columns in series) followed by Hydrophobic Interaction Chromotography 
(HIC) (using an AKTA prime plus FPLC system (GE Healthcare) and a 5 ml HiTrap 
Phenyl column (GE Healthcare)).  HIC was run with a high salt buffer of 1 M 
Ammonium Sulfate with 50 mM Sodium Phosphate (pH 7.0), and a low salt buffer of the 
former only.  MonoPEGylated fractions from HIC were confirmed by Matrix Assisted 
Laser Desorption Ionization Time-Of-Flight mass spectroscopy – MALDI-TOF (Voyager 
DE PRO PerSeptive Biosystems) using a sinapic acid matrix.  Iron citrate (2.5 mole 
excess) in 100 mM sodium bicarbonate was added to the monoPEGylated fraction and 
Formulations 
(Core + no. of Tf) 
Tf measured from 
64Cu Experiment 
Nanoparticle 
Diameter (DLS ) 
Nanoparticle 
Diameter (NTA) 
Zeta Potential in 
KCl (mV) 
Binding Constant, 
Kd (nM) 
5 nm + mPEG 0 21.6 ± 0.2 n.d. -11.4 ± 1.3 - 
5 nm + 3 Tf 3.2 21.0 ± 2.5 n.d. -12.9 ± 0.3 4.9 
5 nm + 6 Tf 4.6 25.3 ± 2.5 n.d. -10.0 ± 1.9 3.1 
20 nm + mPEG 0 46.1 ± 2.7 n.d. -8.3 ± 0.8 - 
20 nm + 10 Tf 7.4 44.6 ± 3.2 n.d. -14.4 ± 2.2 1.7 
20 nm + 20 Tf 9.5 43.6 ± 4.6 n.d. -6.8 ± 0.4 1.5 
20 nm + 30 Tf n.d. 48.3 ± 2.9 n.d. -14.1 ± 1.4 0.71 
20 nm + 100 Tf 49.9 46.3 ± 1.3 n.d. -10.2 ± 2.3 0.018 
50 nm + mPEG 0 78.8 ± 3.1 72.0 ± 1.7 -5.7 ± 1.1 - 
50 nm + 20 Tf n.d. 78.1 ± 2.8 69.7 ± 2.3 -5.3 ± 2.0 0.89 
50 nm + 200 Tf 107.3 85.4 ± 2.9 73.3 ± 2.1 -6.3 ± 0.4 0.014 
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incubated with gentle stirring for 2.5 hours at room temperature.  The excess iron was 
removed with six washes of 100 mM sodium bicarbonate through a 50 kDa centrifugal 
filter.  The iron loading content of transferrin was measured by UV-VIS through the ratio 
of A465/A280 and was compared to the same ratio of the original non-processed holo-
transferrin.  A465/A280 ratios above 0.8 were considered to be adequate evidence for iron 
loading.  Tf-PEG-OPSS was stored at 4 oC in a 50 mM sodium bicarbonate buffer pH 
8.0.  
Au-PEG-Tf Synthesis. Tf-PEG-OPSS was added in the indicated molar fraction (e.g. 10 
mole excess transferrin added to gold for a 10 transferrin per particle formulation) to gold 
cores of 5 nm, 20 nm, and 50 nm (BBI International).  The reaction was stirred for at 
least 90 minutes, and a large excess (~10,000 molar excess) of 5 kDa mPEG-SH (Laysan 
Bio) was added for a remaining 90 minutes.  The resulting 45 nm and 80 nm 
nanoparticles were pelleted at 20,000 g for 10 minutes, and the pellets were resuspended 
in 1 ml of water, sonicated for 10 minutes, and repelleted.  This washing procedure was 
repeated two times.  In lieu of centrifugation for the 20 nm nanoparticles, a 100 kDa 
MWCO spin filter (Amicon) was used to removed excess PEG and concentrate the 
nanoparticles.  
Dynamic Light Scattering (DLS):  Particle sizes and zeta potentials were measured with 
a Brookhaven Instruments DLS and ZetaPALS.  Hydrodynamic diameters were 
measured in PBS and averaged from three runs at two minutes each.  Zeta potentials were 
run in 1.5 mM KCl (pH 7.0) and averaged from three runs at a target residual of 0.02.  
Measurements were reported as the average +/- one standard deviation.     
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Nanoparticle Tracking Analysis (NTA): NTA measurements were performed with a 
NanoSight NS500 (NanoSight).  All measurements were taken in 50 mM sodium 
phosphate (pH 7.0) over a time of 60 s with manual shutter and gain adjustments.  The 
data is reported as the mode with one standard deviation of three runs on the same 
sample. 
Nanoparticle-Cell Binding Assay.  Neuro2A cells (ATCC) were cultured for at least 
one week in DMEM, 10% FBS and PEN/STREP.  Cells were washed once with cold 
PBS, scraped from the flask and suspended in cold PBS, fixed for 15 minutes in cold BD 
Cytofix (BD Biosciences) and resuspended in PBS with 4% BSA.  Increasing 
concentrations of nanoparticles were incubated with 5 x 106 cells at 2.5 x 107 cells/ml for 
90 minutes.  Cells were pelleted at 300 g for 4 minutes, the supernatant/nanoparticles 
were removed, and the cells were resuspended in PBS.  Post incubation with the gold 
nanoparticles, the cells were washed twice with 15 ml of PBS, stained with silver 
enhancement solution, and measured for gold content in a 96 well plate reader (Tecan, 
Infinite M200) (Excitation – 310 nm, Emission – 400 nm).  The data were fit to a 
Langmuir binding isotherm with Bmax and Kd nonlinearly fit with Matlab nlinfit.   
Nanoparticle Transferrin Content.  Iron was dechelated from Tf-PEG-OPSS by 
incubating in sodium maleate solution (pH 5.0) for one hour and removing unbound iron 
with 50 MWCO spin filters (Amicon).  Iron removal was confirmed by measuring 
A465/A280 and comparing to A465/A280 of holo-transferrin.  Tf-PEG-OPSS was 
resuspended in 50 mM sodium bicarbonate (pH 8.0) to which 4 mCi of 64Cu (obtained 
from Isotope Production Group at Washington University, Saint Louis) was mixed and 
incubated for 90 minutes at room temperature.  Tf-PEG-OPSS was concentrated in the 50 
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MWCO spin filter, and unbound copper was removed with a citrate based (pH 7.0) Micro 
Bio-Spin column (Bio-rad). 64Cu labeling of transferrin was tested and confirmed by 
instant thin layer chromatography (ITLC) (Biodex, Tec-Control).  The concentration of 
the radiolabeled Tf-PEG-OPSS was determined using a Nanodrop 2000 (Thermo), and 
the Tf-PEG-OPSS was stirred at room temperature with the indicated ratio of gold 
nanoparticles for at least one hour.  Unbound transferrin was removed by pelleting the 
nanoparticles through centrifugation and removing the transferrin-laden supernatant.  The 
nanoparticles were sonicated and washed with 1.5 ml of water.  Gamma Activities of 
each particle formulation were counted with a gamma counter (Wizard, Perkin Elmer) 
and a standard curve of Tf-PEG-OPSS was generated to determine the bulk amount of 
transferrin attached to the gold. 
Discussion and Conclusion 
 
 A well-defined set of nanoparticles was created that is critical for clearly 
understanding the in-vivo studies that follow.  Dynamic Light Scattering was employed 
with nanoparticle tracking analysis to size the nanoparticles, and the results obtained 
from these two modalities yield sizes that are essentially the same.  NTA demonstrated 
that the nanoparticle population was unimodal (only one size of nanoparticle present in 
each formulation), which gave confidence the DLS measurement were within reason.  
Zeta potentials as measured by Brookhaven’s ZetaPals were all within -5 mV to -15 mV 
and satisfy the requirement that the nanoparticles be slightly negative to near neutral, to 
avoid blood-brain barrier disruption, protein corona formation, and MPS uptake. 
Also, NTA zeta potential analysis gave first insights into the distribution of 
transferrin over the associated nanoparticle population.  A unimodal Poisson distribution 
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was seen across each nanoparticle formulation. This is important to assure the zeta 
potentials and transferrin content of the nanoparticle population is homogeneous and that 
the nanoparticles within the population will act similarly in crossing the blood-brain 
barrier. 
 Nanoparticle transferrin content was directly measured by labeling transferrin 
with positron emitting 64Cu, formulating the nanoparticles with the radiolabeled 
transferrin, and measuring the nanoparticle associated gamma signal.  This gave the first 
direct measurement of transferrin content on gold nanoparticles as previous 
measurements utilized methods such as ELISA that only indirectly measured nanoparticle 
transferrin content through mass balances [12]. 
 Finally this was the first report of a cell binding study that utilizes silver 
enhancement fluorescence for quantification of nanoparticles.  This binding assay has 
provided the first data that clearly shows an increase in binding avidity to cell-associated 
receptors with increasing ligand content within a nanoparticle size.  These data 
demonstrated size effects of binding to the cell and the nanoparticle ligand content effects 
of binding avidity to the cell surface receptors.  It was found that within the nanoparticle 
size range studied that nanoparticle size has a weak effect on binding, and that 
nanoparticle ligand content has a strong relationship with binding avidity. 
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Chapter 4: In-vivo Blood-Brain Barrier Study of 
Transferrin Containing Nanoparticles* 
Introduction 
 
Recently it has been reported that antibodies with high affinity to the transferrin 
receptor strongly attach to the receptor and do not readily detach from the receptor and 
enter the brain parenchyma.  It was shown that these antibodies, when designed to have 
reduced affinity to the receptor, can engage the receptor on the blood side of the blood-
brain barrier and release from the receptor on the brain side of the blood-brain barrier [1]. 
Inspired by this study, nanoparticles of varying avidities to transferrin receptors 
were created to test whether this behavior was also true for nanoparticles targeted to 
transferrin receptors.  Here, we report that transferrin-containing gold nanoparticles can 
reach the brain parenchyma from systemic administration in mice through a receptor 
mediated transcytosis pathway.  This transport is aided by tuning the nanoparticle avidity 
to transferrin receptor, that is correlated to the nanoparticle size and total number of 
transferrin decorating the nanoparticle surface. Nanoparticles of both 45 nm and 80 nm 
diameter reach the brain parenchyma, and their accumulation there (visualized by silver 
enhancement light microscopy in combination with transmission electron microscopy 
imaging) is observed to be dependent on transferrin content (avidity): nanoparticles with 
large amounts of transferrin remain strongly attached to brain endothelial cells, while 
nanoparticles with less transferrin are capable of both interacting with transferrin receptor 
on the luminal side of the blood-brain barrier and detaching from transferrin receptor on 
                                                
* Excerpts of this chapter are reproduced with permission from “Transcytosis and brain uptake of 
transferrin-containing nanoparticles by tuning avidity to transferrin receptor.”  Wiley, D. T., Webster, P., 
Gale, A., & Davis, M. E. Proc. Natl. Acad. Sci. USA. (2013). 
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the brain side of the blood-brain barrier. The necessity of nanoparticles to have proper 
avidity in order to reach brain parenchyma is consistent with recent behavior observed 
with transcytosing antibodies that bind to transferrin receptor [1].   
Results 
 
Accumulation of Targeted Nanoparticles in the Brain Parenchyma is Dependent on 
Transferrin Amount.  
The formulations listed in Table 3.1 were administered to mice by lateral tail vein 
injection.  One mouse was injected per each formulation of the ca. 20 nm nanoparticles 
(after analysis of the tissues (vide infra) a decision was made not to inject additional mice 
with these formulations because the resulting images were conclusively negligible 
relative to the images taken of the ca. 45 nm and 80 nm nanoparticle treated mice).  Three 
mice were injected per 45 nm and 80 nm formulations, and at eight hours post injection 
the brains were resected and processed for silver enhanced imaging.  
Nanoparticles in the parenchyma of each image were quantified and compiled 
into the box plots of Figure 4.1a. These data illustrate how nanoparticle accumulation in 
the brain parenchyma was altered by both nanoparticle size and transferrin content.  
Nanoparticles in the 45 nm and 80 nm size range were observed in the brain parenchyma, 
and statistically significant maximums were obtained within the formulations studied for 
both sizes.  Nanoparticles of ca. 20 nm as well as all formulations with mPEG-only were 
not clearly seen in the parenchyma.   
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Figure 4.1:  a, Quantitation of the nanoparticles observed in the brain parenchyma after 
tail vein injection.  b, Quantitation of 80 nm formulations in the blood vessels.  p-values 
calculated from non-normal distributions by Mann-Whitney U test (Wilcoxon rank sum 
test) of compiled data from all mice investigated in each nanoparticle formulation.  c, 
ICP-MS data of bulk brain gold content from the 80 nm formulations.  
 
In some regions of a few tissue sections, silver enhancement deposited in a pattern 
that we classified as not specific to nanoparticles.  Also, several areas with silver 
enhancement characteristic of nanoparticles were observed and classified as not due to 
a
B.
c
b
*
*
*
*
*
*
*p-value < 0.0001 *p-value < 0.0001
*p-value < 0.0001
p = 0.004
p = 0.015
*
*
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receptor-mediated transcytosis (Figure 4.2).  These events were documented but not 
included in the quantitative analysis.  One brain from a mouse not injected with 
nanoparticles was stained with hematoxylin and silver enhancement solution, and some 
background signal due to silver enhancement was rarely seen in this section (Figure 4.3).  
These non-specific events due to silver enhancement are clearly distinguishable from 
signal in the parenchyma due to gold nanoparticles. 
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Figure 4.2: Examples of silver enhancement signal observed in the brain parenchyma that 
were not considered to be specific to nanoparticle accumulation due to receptor mediated 
transcytosis.  a,  Some large vessels had an excessive amount of silver enhancement 
signal adjacent to the vessel; likely due to tissue processing.  b, Rarely, blotching was 
seen (also seen in the untreated brain) due to silver enhancement deposition in the tissue.  
c, A silver enhancement signal unique to the rostral cortex, the olfactory glomerulus, and 
the cerebellum was observed in some (but not all) sections.  When this staining pattern 
was seen it was difficult to identify nanoparticles, and therefore these nanoparticles were 
not included in the quantitative analysis in order to avoid miscounting. d, At some of the 
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bordering regions of the brain (both in the ventricles and outer periphery of the brain) 
silver enhancement signal that looked to be from gold nanoparticles was present.  It was 
not certain this signal was from receptor mediated transcytosis or artifact from tissue 
processing, and therefore was not included in the quantitative analysis. 
 
 
 
Figure 4.3: Images from the brain of the untreated mouse.  a, Very rarely, some silver 
enhancement deposited in the tissue resulting in non-specific blotching. b, Most of the 
brain is clean of silver enhancement deposition in the large vessels, capillaries and 
parenchyma. 
 
Figure 4.4 presents representative images from a number of the formulations 
studied (full, unmagnified images can be seen in Figures 4.6-4.8). Vessel staining is most 
clear in the images of nanoparticles of the ca. 20 nm formulations that remain largely in 
the vasculature (vessels stained black with a lack of clearly visible nanoparticles outside 
the vasculature).   The images of the 45 nm, 30 Tf and 80 nm, 20 Tf formulations are 
representative of the majority of images taken with clear nanoparticle signal in the 
parenchyma.  The arrow in the 80 nm, 200 Tf image points to a nanoparticle that is out of 
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focus.  Within 5 µm tissue sections, it was impossible to consistently take images where 
all nanoparticles were in focus.  These out-of-focus nanoparticles were also included in 
the quantitative analysis.  
 
Figure 4.4. Sample images from hematoxylin stained and silver enhanced brain sections.  
Included are images from a range of nanoparticle formulations injected systemically with 
brains resected and processed eight hours later.  Black arrows accentuate clearly visible 
nanoparticles. Left column: 20 nm nanoparticles with 6 Tf, 3 Tf, and no Tf (images from 
top to bottom).  Center column: 45 nm nanoparticles with 100 Tf, 30 Tf, and 10 Tf 
(images from top to bottom).  Right column: 80 nm nanoparticles with 200 Tf, 20 Tf, and 
no Tf (images from top to bottom). 
 
 High Transferrin Content Nanoparticles Have Increased Association with Brain 
Endothelial Cells.   
  High binding avidity with high nanoparticle transferrin content reduces the 
parenchymal accumulation of the 45 nm and 80 nm nanoparticles (Table 3.1, Figures 4.1 
and 4.4).  Additionally, high avidity 80 nm nanoparticles (with 200 Tf) consistently 
20 nm 0 Tf               
20 nm 3 Tf
20 nm 6 Tf 45 nm 100 Tf
45 nm 30 Tf
45 nm 10 Tf
80 nm 200 Tf
80 nm 20 Tf
80 nm 0 Tf
10 um
10 um
10 um
10 um
10 um
10 um10 um
10 um
10 um
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remained associated with the blood vessels more than the untargeted 80 nm 
nanoparticles.  To quantify this phenomenon, at eight hours post injection we 
homogenized two brains containing mPEG-only nanoparticles and three brains each of 
the 80 nm nanoparticles containing 20 Tf and 200 Tf, and we measured the total brain 
gold content by ICP-MS (Figure 4.1c).  Additionally, the 80 nm nanoparticle silver 
enhancement signal appeared discrete in the blood vessels (unlike the continuous signal 
of the 20 nm and 45 nm nanoparticles in the vessels), and this vessel-associated 
nanoparticle signal was quantified for each 80 nm formulation and the data compiled in 
Figure 4.1b.   
  Consistent with the vessel-associated nanoparticle content quantified from the 
images, more gold was detected in the bulk brain (vessels and parenchyma) with higher 
nanoparticle transferrin content by ICP-MS. The combination of the vessel analysis, ICP-
MS analysis, and the parenchymal quantitative imaging analysis indicates more 80 nm 
nanoparticles remain in the bulk of the brain with increasing transferrin, not because they 
are entering the brain parenchyma, but because they are largely stuck in or on the 
endothelial cells of the vasculature. 
 TEM Images Show that Nanoparticles Undergo Receptor Mediated Transcytosis 
and are Present in Brain Parenchyma.  
   The 80 nm formulations accumulated in the brain to the greatest extent, so these 
nanoparticles were chosen for additional TEM analysis (Figure 4.5).  All sample images 
were taken from the cerebral cortex.  No untargeted 80 nm nanoparticles were found in 
the endothelial cells or brain parenchyma after several hours of imaging, though they 
were seen in the vessel lumen – consistent with the light microscopy data.  Nanoparticles 
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with low (20Tf/nanoparticle) and high (200 Tf/nanoparticle) amounts of transferrin were 
both observed in endothelial cells, as well as in the parenchyma (Figures 4.5a-d). 
Nanoparticles visualized inside endothelial cell vesicles (e.g., Figure 4.5b), suggest a 
trans-cellular route of delivery to the brain parenchyma.  Untargeted nanoparticles were 
not observed inside endothelial cells, and all 80 nm formulations had similar zeta 
potentials, suggesting that the transferrin coated nanoparticles entered into the endothelial 
cells via a transferrin receptor-mediated process. Note the reduced quality of tissue 
microstructures in these images that can be attributed to the method of tissue processing 
needed to see extracellular nanoparticles (mice underwent CO2 asphyxiation followed by 
brain resection and immediate submersion in formalin solution).  Higher quality cellular 
microstructures are preserved with a perfusion fixation technique (Figures 4.5e-i). 
  Nanoparticle-associated toxicity has been suggested to degrade the blood-brain 
barrier [2], that may be a contributing factor to nanoparticle access to the brain 
parenchyma.  Cardiac perfusion-fixation with a solution of fixative containing blood-
brain barrier impermeable TEM contrast agent lanthanum nitrate has previously been 
used to ensure the blood-brain barrier integrity is intact [3]. Each 80 nm nanoparticle 
formulation was injected, and cardiac-perfusion fixation was performed eight hours post 
injection.  In all three brains, lanthanum remained exclusively within the vasculature 
(strongly staining glycocalyx on the surface of the endothelial cells with partial 
interendothelial cleft staining) and no sub-endothelial staining was seen (e.g., Figure 4.5f-
g).  Additionally, no nanoparticles were observed in the lumen of the vessels after 
vascular perfusion, though transferrin coated nanoparticles were again localized in the 
endothelial cells and parenchyma (Figure 4.5h-i).  The blood-brain barrier therefore 
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remains intact and is not permeabilized to large ions after exposure to the 80 nm gold 
nanoparticle formulations.  An intact blood-brain barrier that only allows transferrin-
associated nanoparticles to reach the parenchyma demonstrates the transferrin targeted 
nanoparticles reach the brain through a receptor-mediated transcytosis pathway.   
  
  
92 
 
 
Figure 4.5. (Mi-Mitochondria, Lu-Lumen, En-Endothelial Cell, Pa-Parenchyma, EC-
Endothelial Cleft, NP-Nanoparticle, Gly-Glycocalyx) a, 80 nm, 20 Tf nanoparticle in the 
parenchyma. b, 80 nm, 20 Tf nanoparticle inside a vesicle of the blood-brain barrier 
endothelial cell. c, 80 nm, 200 Tf nanoparticles in the parenchyma.  d, 80 nm, 200 Tf 
nanoparticle near the basal surface of an endothelial cell. e, Perfusion fixation with 
lanthanum nitrate showing lanthanum penetrating the interendothelial cleft with no 
subendothelial staining.  f,g, 80 nm particles injected followed by perfusion fixation eight 
hours post injection.  Both the 20 Tf/Au formulation (f) and the 200 Tf/Au formulation 
(g) do not degrade the blood-brain barrier tight junctions to lanthanum nitrate as the same 
interendothelial cleft penetration with no subendothelial staining is seen. h, 80 nm, 200 
particle inside, and near the apical surface of the endothelial cell.  (Note: The lanthanum 
nitrate-stained glycocalyx separated from the cell surface due to the use of the electron 
beam during imaging.) i, 80 nm, 200 Tf particle found within the brain parenchyma after 
perfusion fixation. 
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Methods 
 
Animal Studies. All animals were treated according to the NIH Guidelines for Animal 
Care and Use as approved by the Caltech Institutional Animal Care and Use Committee. 
Female Balb/c mice (Jackson Laboratory) received i.v. doses of nanoparticles in 150 ul of 
PBS through the lateral tail vein.  Injected doses were as follows: 20 nm gold = 5 x 1013 
nanoparticles/mouse, 45 nm gold = 2.9 x 1012 nanoparticles/mouse, 80 nm gold = 4.5 x 
1011 nanoparticles/mouse. When processing for light microscopy and TEM imaging, the 
mice were euthanized by CO2 overdose.  For TEM perfusion fixation analysis, mice were 
deeply anesthetized with 3% isoflurane, the skin over the ventral thorax was incised and 
the thorax opened to expose the heart.  The right atrium was clipped and the left ventricle 
was perfused with 10% sucrose followed by the fixative (4% paraformaldehyde, 0.05% 
glutaraldehyde, 5% lanthanum nitrate in 100 mM sodium cacodylate buffer, pH 7.2) at 
300 mm Hg using a Perfusion One perfusion pump system (Leica Neurolabs).  After 
fixation, the brain was removed and placed in 4% paraformaldehyde for further tissue 
processing.  
Transmission Electron Microcopy: 500 µm vibratome sections were additionally fixed 
in 2.5% glutaraldehyde (in 0.1 M sodium cacodylate, pH = 7.4) for 2 hours, stained by 
1% OsO4 on ice for two hours, and 0.9% OsO4 and 0.3% K4Fe(CN)6 at room temperature 
for 2 hours. Gradual dehydration with ethanol and propylene oxide enabled tissue 
embedding in Epon 812 resins (Ted Pella). Vibratome sections of the fixed brains were 
flat embedded in order to select specific regions of the brain for further sampling.  
Cerebral sections of the brains were cut from the epoxy block with a diamond wire hand 
saw and re-embedded in epoxy resin for ultramicrotome sectioning.  180 nm thick 
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sections were deposited on carbon and formvar-coated, 200-mesh, copper grids (Electron 
Microscopy Sciences) and stained with 3% uranyl acetate and Reynolds lead citrate (15 
minutes each) for visualization under a 80 kV TF30UT transmission electron microscope 
(FEI, Tecnai). 
Light Microscopy: Resected tissues were fixed in fresh 4% paraformaldehyde (in PBS 
pH 7.0) overnight, dehydrated in increasing concentrations of ethanol (3 x 30 minutes 
each), equilibrated in xylenes (3 x 30 minute washes) and equilibrated in 50% 
xylene/50% molten paraffin (30 minutes).  The tissues were placed in pure molten 
paraffin (3 x 1 hour), placed in a paraffin mold, allowed to cool, and 5 µm sections were 
obtained.  Sections were deparafinized with xylenes, rehydrated with serial dilutions of 
ethanol.  To visualize gold nanoparticles, the silver enhancement kit for light and electron 
microscopy (Ted Pella) was used as indicated by the manufacturer – silver enhancement 
was allowed to incubate on the tissue section for approximately 20 minutes.   After 
hematoxylin counterstaining, the sections were re-dehydrated with ethanol and xylenes, 
and mounted with Permount (Fisher). All light microscopy images were taken on an 
Olympus IX50 microscope with a 40x objective using QCapture Pro imaging software 
(QImaging).   
Image Analysis, Particle Counting, and Statistics: All images were taken from 
sections as close to the mid sagittal plane as possible (one section imaged per brain).  40 
images were taken of each tissue section, with images taken from throughout four regions 
of the brain (10 images per region): rostral, dorsal, and ventral regions, and the 
cerebellum.  Within each region the images were acquired with a sequential random 
sampling method: beginning from a randomly chosen starting point images were taken at 
  
95 
set intervals using transverse scans that spanned most of the tissue section.  Nanoparticles 
visualized in the parenchyma and 80 nm nanoparticles visualized in the vessels were 
manually counted and the data was binned in Matlab.  Pairwise comparison groups (e.g. 
80 nm 20 Tf vs. 80 nm 200 Tf) of the non-normal distributions were analyzed for 
statistically significant differences using a Mann-Whitney U test (Wilcoxon rank sum 
test) and p-values reported in Figure 4.1.  Image brightness and contrast were adjusted 
using "Levels" and "Curves", and all adjustments were applied to the whole image.  In 
some instances (H&E images), color was adjusted using "Levels" to match the other 
images in the figure. This adjustment was applied to the whole image.  All adjustments 
were made using Adobe PhotoShop.  
ICP-MS.  Brains were microwaved in aqua regia (70% HNO3 and 30% HCl in a 3:1 
volume ratio) until they were fully homogenized.  20.5 mL of deionized water were 
added and the sample was centrifuged at 3200 g for 15 min to remove cell debris.  The 
supernatant was analyzed for gold content using an HP 4500 ICP-MS (Agilent). 
Nebulization occurred with a flow of 1.3 L/min of argon using a Babbington type 
nebulizer in a Pyrex Scott-type spray chamber. The argon plasma power was 1200 W 
with a flow of 15 L/min and an auxiliary flow of 1.1 L/min. A calibration curve of 
various concentrations of unmodified gold nanoparticles was used to measure the gold 
content, using 2.5% HNO3 and 0.42% HCl as the blank solvent. Reported values are 
expressed as the percent of injected dose per gram of brain tissue. Error bars represent the 
standard error from the measurements taken from each group of mice. 
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Supplemental Figures 
 
Figure 4.6.  Low and high magnification images of 20 nm nanoparticles.  Left column: 
low magnification images; right column: high magnification images.  Top row: 0 Tf; 
center row: 3 Tf; bottom row: 6 Tf. 
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Figure 4.7. Low and high magnification images of 45 nm nanoparticles.  Left column: 
low magnification images; right column: high magnification images.  Top row: 10 Tf; 
center row: 30 Tf; bottom row: 100 Tf. 
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Figure 4.8. Low and high magnification images of 80 nm nanoparticles.  Left column: 
low magnification images; right column: high magnification images.  Top row: 0 Tf; 
center row: 20 Tf; bottom row: 200 Tf. 
 
Discussion 
 
  Nanoparticles in the sub-100 nm diameter size range have now been shown to be 
able to move through brain tissue [4]. Thus, if these nanoparticles can transcytose across 
the intact blood-brain barrier, they may be very useful in delivering a broad spectrum of 
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therapeutic and imaging agents. Of major importance is to show that it is truly the 
nanoparticle that is reaching the brain parenchyma, and that it is doing so without 
damaging the blood-brain barrier. Motivated by the results of Yu et al. [1], and by the 
fact that the avidity of nanoparticles can be altered by targeting ligand choice and number 
density, we prepared a series of targeted nanoparticles that had a range of avidities for the 
transferrin receptor. The results from measuring the avidities for the transferrin receptors 
on Neuro2A cells showed that avidities were altered by both the nanoparticle size and the 
total number of transferrin molecules decorated on the nanoparticle surface. This set of 
targeted nanoparticles was investigated for their ability to interact with and transcytose 
across the blood-brain barrier in mice. Our results show that nanoparticle avidity does 
play a significant role in the transcytosis behavior. Nanoparticles with the highest 
avidities were bound to the blood-brain barrier but had reduced accumulation in the brain 
parenchyma relative to nanoparticles with reduced avidities. If the avidity is too low, then 
nanoparticles did not engage the blood-brain barrier.  
The necessity for having a particular avidity to allow transcytosis of targeted 
nanoparticles is consistent with behavior observed with transcytosing antibodies to 
transferrin receptor [1].  Nanoparticles with high avidity can have similar binding 
dissociation constants to typical antibodies, and much like the antibodies of high affinity, 
these nanoparticles engage the blood-brain barrier but do not appreciably enter the brain 
parenchyma.  Nanoparticles with lesser avidities were able to reach the brain parenchyma 
most likely due to the release of the nanoparticles upon transcytosis. If the avidity is too 
low, the nanoparticles in circulation do not engage transferrin receptors on the blood-
brain barrier as the nanoparticles are likely out competed by the inherent mouse 
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transferrin in blood for the available transferrin receptors.  These results show that 
targeted nanoparticles can be prepared and their avidities tuned to allow for transcytosis 
across the blood-brain barrier. The avidity, along with nanoparticle size and surface 
charge, need to be controlled in order to have intact nanoparticle transcytose across the 
blood-brain barrier without alteration of its properties. Currently, we are exploring these 
nanoparticle design rules to prepare targeted nanoparticles with therapeutic agents.   
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Chapter 5:  Summary and Conclusion 
 
Inspired by the increasing rates of brain disease morbidity and mortality the 
nation will face over the next 50 years, a national initiative was created to develop new 
strategies for treating brain diseases such as Alzheimer’s disease [1, 2].  In order to 
successfully treat diseases of the brain, therapeutics must cross the blood-brain barrier so 
they can reach the site of pathology and enact a therapeutic benefit.  Most therapeutics do 
not cross the blood-brain barrier [3], and many therapeutics currently being developed 
will not be successful in treating their target disease not because they lack functionality, 
but simply because they cannot reach the brain.  As an example, dopamine cannot access 
the brain for the treatment of Parkinson’s disease, however the dopamine analogue, L-
DOPA, is able to cross the blood-brain barrier and be converted into dopamine by brain-
associated decarboxylases [4, 5].  Usage of nanoparticles as drug delivery vehicles for 
therapeutics will allow future investigators the freedom to create new therapeutics 
independent of blood-brain barrier permeability considerations.  These nanoparticles can 
encapsulate the therapeutics, and deliver them across the blood-brain barrier. 
The blood-brain barrier has been a major bottleneck in the development of new 
therapeutics for brain diseases [3].  Nanoparticles may be able to deliver therapeutics 
across the blood-brain barrier regardless of the therapeutic size or chemical composition 
(e.g. [6]).  Nanoparticles may be able to be delivered to the brain through receptor 
mediated transcytosis by creating nanoparticles that attach to receptors on the blood brain 
barrier that transcytose [7].  In this work, Ecgp96, a receptor that reportedly is only 
accessible from the blood at the blood-brain barrier [8] and is thought to be capable of 
facilitating receptor-mediated transcytosis, was studied as a receptor that could 
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potentially deliver nanoparticles only to the brain.  Additionally, nanoparticle designs and 
the understanding of how to optimize these designs to facilitate receptor-mediated 
transcytosis across the blood-brain barrier were investigated here.  Gold nanoparticles 
were synthesized with varying sizes and varying targeting ligand contents.  The 
nanoparticles were systemically injected into mice in order to determine their interactions 
with and transcytosis behaviors at the blood-brain barrier.  These studies provided 
information on how to properly design nanoparticles that safely and efficiently cross the 
blood-brain barrier. 
Though many receptors have been shown to be located at the blood-brain barrier 
and facilitate receptor mediated transcytosis of their endogenous ligands [7, 9-14], most 
of these traditionally targeted receptors are accepted to be ubiquitously expressed and 
would indiscriminately deliver the nanoparticles into cells throughout the body.  
Motivated by collaborators that work on infectious diseases, focus was placed on 
designing nanoparticles that are inspired by bacteria that are known to cause infections of 
the brain (such as OmpA positive E. coli [15, 16]).  A strategy was proposed to target 
nanoparticles to the same receptors at the blood-brain barrier that these pathogens 
reportedly used to cross into the brain.  One such receptor associated with neonatal E. 
coli meningitis was E. coli glycoprotein 96 (Ecgp96) that was reported to be only 
accessible from the blood at the blood-brain barrier [8], and that could potentially deliver 
nanoparticles into and across endothelial cells only at the blood-brain barrier. 
The accumulated results from the PET/CT, SPECT/CT, Fluorescence Xenogen 
imaging, MRI, and confocal microscopy studies indicated that Ecgp96 is located within 
the endothelial cells of the blood-brain barrier; however Ecgp96 is not accessible to 
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antibodies from the blood.  PET/CT imaging demonstrated that there was no gross 
accumulation of antibodies to Ecgp96 in the brain, and ROI analysis confirmed that there 
was no measurable accumulation of antibody in the brain beyond the levels of antibody 
found in the blood.  Confocal microscopy studies of sectioned brain tissue demonstrated 
that Ecgp96 did reside within the endothelial cells at the blood-brain barrier but was not 
located on the surface of the endothelial cells.   
 Because E. coli meningitis is a disease of newborn infants, SPECT/CT based 
biodistribution studies were performed on neonatal mice to determine if Ecgp96 was 
located on the endothelial cells of newly born mice.  These SPECT/CT studies 
demonstrated that Ecgp96 was also not accessible from the blood on the blood-brain 
barrier endothelial cells of three-day-old mice.  Most importantly it was shown that 
Ecgp96 cannot be accessed from the blood on blood-brain barrier endothelial cells in 
mice and therefore it cannot serve as a target receptor for receptor-mediated transcytosis 
of nanoparticles across the blood-brain barrier. 
 Though it was determined that Ecgp96 was not accessible from the blood, these 
studies provided new information about the possible pathogenesis of E. coli meningitis in 
newborn infants.  Confocal microscopy and flow cytometry studies of cultured brain 
endothelial cells showed that Ecgp96 may be located on the surface of cultured cells and 
that the presence of OmpA in culture may increase the expression of Ecgp96 on the 
surface of the cells.  The in-vivo studies demonstrate that Ecgp96 is not normally located 
on the surface of blood-brain barrier endothelial cells in-vivo, however the in-vitro 
studies suggest that the presence of OmpA positive E. coli may cause the endothelial 
cells to transport Ecgp96 to the cell surface, which is consistent with reports of Ecgp96 
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on the cell surface after loss of endoplasmic reticulum retention sequence KDEL [17].  If 
OmpA stimulates the expression of Ecpg96 on the surface of the endothelial cell in-vivo, 
further E. coli OmpA-Ecgp96 interactions may help facilitate the passage of the E. coli 
into the brain through some undetermined mechanism.  Confirmatory in-vivo studies 
remain to be performed by an infectious disease lab. 
 In order to move forward with determining how to design nanoparticles that can 
cross the blood-brain barrier, a receptor was chosen that is known to exist on the blood-
brain barrier and facilitate the transport of its ligand to the brain.  The receptor chosen 
was the transferrin receptor which facilitates the transport of iron into the brain through 
its carrier protein, transferrin.  The transferrin receptor has been used for multiple blood-
brain barrier transcytosis studies of antibodies [7, 18-19] and nanoparticles [20-22].  
Recently it has been reported that antibodies with high affinity to the transferrin receptor 
strongly attach to the receptor and do not readily detach from the receptor and enter the 
brain parenchyma.  It was shown that these antibodies, when designed to have reduced 
affinity to the receptor, can engage the receptor on the blood side of the blood-brain 
barrier and release from the receptor on the brain side of the blood-brain barrier [19, 23]. 
 Inspired by the antibody study, nanoparticles of varying avidities to transferrin 
receptors were created to test whether this behavior was also true for nanoparticles 
targeted to transferrin receptors.  Nanoparticles of varying sizes and transferrin contents 
were created and their sizes, zeta potentials, transferrin contents and binding avidities to 
mouse cell transferrin receptors were measured.  Within a nanoparticle size, it was shown 
that nanoparticle binding strength to mouse transferrin receptors is directly related to the 
transferrin content of the nanoparticle.  Also, within the size range reported, it was shown 
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there was only a weak effect of size on the nanoparticle binding strength to the cells.   
Many nanoparticle-based studies do not quantify the amount of nanoparticle that 
reaches the brain (e.g. [6]), and many that do utilize a capillary depletion method that 
does not clearly distinguish nanoparticle that remains stuck in or on the endothelial cells 
as opposed to nanoparticle that enters the brain parenchyma [24].  A silver-enhancement 
method was developed in this work that can clearly visualize nanoparticles under light 
microscopy and can clearly distinguish vessel-associated nanoparticles from parenchyma-
associated nanoparticles.  These images are taken on an appropriate size scale for 
counting multiple nanoparticles within a single field of view.  This silver enhancement 
quantification method provided information on how many nanoparticles remained 
associated with the vessels in comparison to how many nanoparticles released from the 
vessels and entered the brain parenchyma.  It was found that nanoparticles of both 45 nm 
and 80 nm diameter reached the brain parenchyma, and their accumulation there was 
observed to be dependent on transferrin content. Nanoparticles with large amounts of 
transferrin remain strongly attached to brain endothelial cells, while nanoparticles with 
less transferrin are capable of both interacting with transferrin receptor on the luminal 
side of the blood-brain barrier and detaching from transferrin receptor on the brain side of 
the blood-brain barrier.   
  The silver enhancement quantification method was also useful for counting the 
number of 80 nm nanoparticles that remained associated with the blood vessels after 
eight hours of circulation.  The nanoparticles with large amounts of transferrin remained 
more highly associated with the vessels, which is consistent with the ICP-MS studies of 
the bulk brain gold content (gold in both vessels and parenchyma) that showed more 
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nanoparticle remained in the bulk of the brain with higher nanoparticle transferrin 
content. In combination these studies indicate more 80 nm nanoparticles remain in the 
bulk of the brain with increasing transferrin, not because they are entering the brain 
parenchyma, but because they are largely stuck in or on the endothelial cells of the 
vasculature.  This finding is consistent with the analysis provided by Paris-Robidas [25] 
and the results of the antibody based study by Yu et al. [19]. 
  Furthermore, TEM imaging studies of 80 nm nanoparticles demonstrated that 
transferrin-containing nanoparticles entered the endothelial cells of the blood-brain 
barrier and entered the brain parenchyma, but untargeted nanoparticles did not.  A 
lanthanum nitrate blood-brain barrier permeability study after systemic injection of the 
nanoparticle formulations demonstrated that the nanoparticles did not degrade the blood-
brain barrier integrity and that the nanoparticles did not access the brain through the 
paracellular route, but were transported into the brain through transferrin-receptor 
mediated transcytosis. 
  This study is critical for understanding how to properly design nanoparticles that 
can safely and efficiently enter the brain parenchyma to deliver a therapeutic payload.  
Most importantly, it was concluded that the avidity of the nanoparticle to the receptors 
must be tuned to maximize the amount of nanoparticle that reaches the brain parenchyma.  
This avidity can be mildly adjusted by the nanoparticle size (within the 20 nm to 100 nm 
size scale), and can be mainly tuned by the total ligand content of the nanoparticle. 
  This study also provides insight into the current state of nanoparticle delivery to 
the brain.  Very little of the injected dose of the optimized nanoparticle formulation 
reached the brain parenchyma.  Less than 1% of the injected dose per gram entered the 
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bulk of the brain as measured by ICP-MS, and only a fraction of that amount exited the 
vessels and entered the brain parenchyma as observed in the silver enhanced light 
microscopy images.  These amounts are very small and consistent with the amounts of 
optimized antibodies that reached the brain parenchyma as reported by Yu et al. [19].  
Further work needs to be done to increase the amount of nanoparticles reaching the brain. 
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